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ABSTRACT
The Acute Effects of Transdermal Testosterone Precursor Administration
on Serum Steroid Hormone Levels in Females

by
Mark Anthony Rasmussen
Dr. Lawrence Golding, Examination Committee Chair
Distinguished Professor o f Kinesiology
University o f Nevada, Las Vegas

Most governing sports authorities have banned the use o f anabolic steroids as
ergogenic aids. Recently, a transdermal testosterone precursor dietary supplement
(AndrosteDERM®) has become available; athletes can apply the cream to their skin with
the belief that it w ill increase serum testosterone levels, muscle mass, and strength. The
purpose of this study was to measure the effects of one m illiliter of AndrosteDERM®
applied to the inner surface of the upper arm on the serum levels of androstenedione, and
free and total testosterone in female subjects. Serum levels were measured before
application and every 45 minutes thereafter for six hours. Serum androstenedione, and
free and total testosterone levels were analyzed using radioimmunoassay. Although the
trend seemed to indicate that serum levels did not rise after application, several subjects
had physiologically impossible values, which appear to be due to methodological errors.
That information, along with the initial small number of subjects made the use of
statistical treatment unwise and inferences about the population impossible.
iii
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CHAPTER 1

INTRODUCTION

Athletes often use ergogenic aids in an attempt to gain an edge over their
competitors. An ergogenic aid can be defined as any substance or technique used to
improve athletic performance (Brooks, Fahey, White, & Baldwin, 2000). In ancient
times, athletes and soldiers would consume specific animal parts to obtain the strength,
speed, or agility associated with that animal (Brooks et al., 2000). Today, the use of
ergogenic aids in sports is universal. Dietary supplements are some o f the most popular
and widely used of all ergogenic aids. The use o f dietary supplements, including amino
acids, caffeine, creatine, and protein powders is prevalent in almost every sport today, in
both males and females.
Recently, dietary supplementation o f androstenedione, a precursor to the hormone
testosterone, has gained interest as a method to improve performance by increasing
muscle mass and strength. Many of the manufacturers o f dietary supplements have
started to market new products known as testosterone precursors, or “prohormones” , with
androstenedione being the most popular. Prohormones are marketed with the claim that
their use w ill cause an increase in endogenous testosterone production, acting in much
same way as anabolic steroids (McArdle, Katch, & Katch, 1999). When anabolic
steroids are added to athletes’ training, increases in muscle size and strength and gains in
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total and lean body mass have been reported (Stamford & Moffatt, 1974; Friedel, Dettori,
Hannan, Patience, & Plymate, 1991; Bhasin, Storer, Berman, Callegari, Clevenger,
Phillips, Bunnell, Tricker, Shirazi, & Casaburi, 1996).
To date, very little research has been conducted on the effectiveness of
testosterone precursor supplementation. Most o f the research has investigated oral
androstenedione supplementation, with mixed results. Some studies have shown an
increase in testosterone levels in the body (Earnest, Olson, Broeder, Breuel, & Beckham,
2000; Leder, Longcope, Gatlin, Ahrens, Schoenfeld, & Finkelstein, 2000), while most
others have not (Ballantyne, Phillips, MacDonald, Tamopolsky, & MacDougall, 1999;
Brown, Kohut, Franke, Jackson, Vukovich, & King, 1999; Brown, Reifenrath, Uhl,
Sharp, & King, 1999; King, Sharp, Brown, Reifenrath, & Uhl, 1999; King, Sharp,
Vukovich, Brown, Reifenrath, Uhl, & Parsons, 1999; Parsons, Sharp, Brown, Reifenrath,
Uhl, & King, 1999; Quindry, Brittingham, Panton, Breuel, Earnest, Olson, & Broeder,
1999; Rasmussen, Volpi, Gore, & Wolfe, 2000; Reifenrath, Sharp, Brown, Uhl, & King,
1999; Wallace, Lim, Cutler, & Bucci, 1999). None o f the studies have investigated the
effects of testosterone precursor supplementation in females.
Recently, new methods of testosterone precursor delivery have been developed,
which are touted to be superior to oral ingestion. Sublingual and transdermal versions of
testosterone precursors are now available. The benefits o f these new delivery methods
include absorption directly into the bloodstream, thus bypassing the rapid initial
breakdown in the liver, and faster action because o f the absorption directly into the
bloodstream. One such product is the transdermal version AndrosteDERM®, which
contains the testosterone precursors androstenedione and androstenediol.
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Purpose o f the Study
The purpose o f this study was to evaluate the acute effects of transdermal
testosterone precursor supplement (AndrosteDERM®) administration on the serum
steroid hormone levels of androstenedione and free and total testosterone in females.

Need for the Study
Testosterone precursor supplements are very popular and widely used by athletes
of both sexes, in many different sports. Studies to date have been inconclusive as to
whether or not these supplements have any ergogenic effects. To date, no studies have
investigated the effects o f testosterone precursor administration in females. The effects
o f a transdermal delivery method also have not been tested.

Limitations
1.

Since the sample size was small, seven subjects, and homogeneous, collegeaged females, the generalization of the results should be done with caution.

2.

Because some o f the results obtained from the radioimmunoassay procedure are
in question, the concentrations of serum androstenedione and free and total
testosterone may not be exact.

3.

AndrosteDERM® is one o f several different types o f testosterone precursors.
The results obtained from using another type o f testosterone precursor or
another delivery system may be different.
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Assumptions
1.

Participants had normal baseline androstenedione and free and total
testosterone levels for females.

2.

AndrosteDERM® was absorbed into the bloodstream in 6 hours.

Statement of Hypotheses

Null Hypotheses
Ho:

Acute AndrosteDERM® administration w ill not increase serum androstenedione
levels within six hours o f application.

Ho:

Acute AndrosteDERM® administration w ill not increase serum free testosterone
levels within six hours o f application.

Ho:

Acute AndrosteDERM® administration w ill not increase serum total testosterone
levels within six hours o f application.

Alternate Hypotheses
Hi :

Acute AndrosteDERM® administration w ill increase serum androstenedione
levels within six hours o f application.

Hi :

Acute AndrosteDERM® administration w ill increase serum free testosterone
levels within six hours o f application.

Hi :

Acute AndrosteDERM® administration w ill increase serum total testosterone
levels within six hours o f application.
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CHAPTER 2

LITERATURE REVIEW

Anabolic Steroids and Testosterone
Anabolic steroids are synthetic derivatives o f the male sex hormone testosterone.
Anabolic steroids can be defined as steroids whose function is to stimulate protein
synthesis (Ariel, 1972). Because anabolic steroids have inseparable anabolic and
androgenic properties, they should correctly be called anabolic-androgenic steroids. It is
the anabolic effects, such as anticatabolism, enhanced neural conduction, and increased
skeletal muscle mass that are desired by those who use them, and the androgenic, or
masculinizing, effects that lead to the undesirable side effects (Fahey, 1998; Blue and
Lombardo, 1999). Since the 1940’s attempts have been made to synthesize a steroid that
is completely anabolic, without any o f the unwanted androgenic side effects (Blue and
Lombardo, 1999). To date, all attempts have failed. The anabolic and androgenic effects
o f these drugs are not due to different actions, but instead result from the interaction of
the drug with the same receptor molecule in different tissues (Wilson, 1988).
Testosterone is produced endogenously in the interstitial cells o f Leydig in the
testes (Blue and Lombardo, 1999). Like all steroid hormones, testosterone is synthesized
from cholesterol. Loebel and Kraemer (1999) indicated that the rate-limiting step in the
synthesis o f testosterone is the conversion o f cholesterol to pregnenolone, which takes
5

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

place in the mitochondria. According to Lamb (1989) and Hough (1990), the testes
secrete between 4 and 10 mg/day of testosterone in normal adult males. Mean
testosterone production in males is approximately 8 mg/day (George, 1988). The plasma
concentration of testosterone in males is approximately 3-9 ng/ml, of which, 95% or
more is secreted by the testes (Gard, 1998). In females, the plasma testosterone
concentration is 0.2-0.7 ng/ml (Gard, 1998), all of which is produced by the ovaries and
the adrenal glands (Schânzer, 1996), primarily the adrenal glands (Laycock & Wise,
1996).
Testosterone (Figure 1) is secreted after receiving a signal from luteinizing
hormone, which is secreted from the pituitary gland (Alen & Rahkila, 1988). Loebel and
Kraemer (1999) state that the hypothalamus secretes luteinizing hormone-releasing
hormone, which causes luteinizing hormone to be released from the anterior pituitary
gland. The amount o f luteinizing hormone secreted from the pituitary gland is controlled
by the amount of testosterone in the blood via a negative feedback loop (Brooks, 1983).
Testosterone is responsible for the normal growth and development o f the male
sex organs and maintenance of secondary sexual characteristics, including facial, pubic,
chest, and axillary hair growth, enlargement o f the larynx, sperm production, and
alterations in body musculature and fat distribution (Fahey, 1998; Blue & Lombardo,
1999). Testosterone is also responsible for the greater muscle mass in men when
compared to women (Wyiui, 1975). In both males and females, testosterone increases
libido (Goodman, 1994). Testosterone in females is responsible for some secondary
sexual characteristics, including pubic and axillary hair growth (George, 1988).
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TESTOSTERONE

Figure I; Testosterone Chemical Structure

The most active form o f testosterone is the free, unbound form, which accounts
for 2% o f the total testosterone in the body (Loebel & Kraemer, 1999). Testosterone
bound to albumin accounts for 38% o f the total testosterone; the remaining 60% is bound
to sex hormone-binding globulin (Loebel & Kraemer, 1999). It is the testosterone that is
not bound to sex hormone-binding globulin that is available for metabolism (Loebel &
Kraemer, 1999).
Testosterone is rapidly metabolized by the enzyme SP-reductase (Goodman,
1994) in the liver, into various I7-keto steroids, mainly androstenedione and then to
either androsterone or one of its two isomers, epiandrosterone or etiocholanone (George,
1988). The liver is the main site of testosterone degradation, with the subsequent release
o f water soluble sulfates (Goodman, 1994) and testosterone glucuronide (Hackney, 1998)
into the blood for excretion in the urine (Goodman, 1994). When taken orally.
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testosterone is absorbed into the portal blood circulation and is rapidly degraded by the
liver, leading to insignificant amounts reaching systemic circulation (Wilson & Griffin,
1980). Testosterone that is injected intramuscularly is rapidly absorbed from the
injection site and degraded (Wilson & G riffin, 1980). Therefore, modifications have
been made to the testosterone molecule to alter its metabolism and get around these
complications. In order for serum testosterone levels to be maintained (during
replacement therapy), testosterone esters are injected intramuscularly, or slowly
metabolized oral derivatives are ingested (Wilson & G riffin, 1980).
Three general types o f modifications have been created, estérification o f the 1?Phydroxyl group, alkylation o f the 17a- position, and a modification o f the ring structure
(Wilson & G riffin, 1980). Estérification of the 17P-hydroxyl group prolongs the
duration of time the steroid is active, thus augmenting the effects (Wilson & G riffin,
1980). The more carbon molecules in the acid ester, the more prolonged the action o f the
anabolic steroid (Wilson & G riffin, 1980). Forbes (1985) stated that nitrogen balance
studies have demonstrated that intramuscular anabolic steroids have more prolonged and
greater effects. A 17-a methyl or -ethyl group is common on most orally active anabolic
steroids (Wilson & G riffin, 1980). The 17a-alkylation o f an orally active anabolic
steroid slows the breakdown by the liver; for this reason, all I7a-alkylated anabolic
steroids are toxic to the liver (George, 1988). Some substitutions made to the 2,9, and 11
carbons o f the testosterone molecule (ring structure) also appear to enhance anabolic
activity (Wilson & G riffin, 1980). It could be reasoned that because exogenous
testosterone must be modified to exhibit any sustained effects on the body, an unmodified
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precursor to testosterone such as androstenedione or androstenediol would meet a similar
fate as unmodified testosterone (rapid metabolism by the liver).
Medicinally, anabolic steroids have been used to treat a variety of disorders in the
body including male hypogonadism, certain anemias, bone marrow failure, breast cancer
in postmenopausal women, hereditary angioneurotic edema, osteoporosis, and disorders
where catabolism and negative nitrogen balance are favored, such as wasting illnesses
and patients recovering from severe trauma or surgery (Wilson & G riffin, 1980; Wilson,
1988; Hough, 1990). Haupt and Rovere (1984) report that anabolic steroids were first
given to German troops during World War II to increase their aggression. At about the
same time, anabolic steroids were also used for their ability to restore positive nitrogen
balance in starvation victims (Ryan, 1981). Hough (1990) indicated that athletes first
used anabolic steroids in 1953. In 1954, a Russian team physician told Dr. John Zeigler,
a physician for the United States Weightlifting team, that the Russian weightlifters were
using anabolic steroids to augment their training (Street, Antonio, & Cudlipp, 1996).
One year later. Dr. Zeigler developed methandrostenolone (Dianabol) and introduced it to
the United States weightlifting team (Street et al., 1996). In 1968, the International
Olympic Committee placed anabolic steroids on its list of banned substances (Hough,
1990). Since that time anabolic steroids use has become very popular in sports. They
were initially used mainly by power athletes, those involved in football, weightlifting,
and field events (shot put and hammer throw). Now, their use is seen in sports that do not
rely as heavily on power, including baseball and tennis. Some (Haupt & Rovere, 1984)
believe that anabolic steroid use by athletes has reached almost epidemic proportions in
most sports. Athletes use anabolic steroids in the belief that they w ill increase body and

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

10

muscle mass, muscular strength and aggressiveness (Hough, 1990; Fahey, 1998). Wade
(1972) stated that winning at the Olympics has become a question o f which country has
the best doctors and chemists.

Anabolic Steroid Research
Since athletes first used anabolic steroids, there has been great debate whether
they actually improve performance (Wagner, 1991). In an attempt to determine whether
or not anabolic steroids improve performance, researchers have studied their effects, with
mixed results. The majority o f anabolic steroid research was performed during the
1970’s. Most early studies were of poor quality and had mixed results (Wagner 1991;
Blue & Lombardo, 1999). The scientific studies are fraught with methodological
problems that make interpretation difficult and comparisons between studies confusing
(Lombardo, 1993). Ryan (1981) stated that conclusions were drawn that were not
justified by the results obtained.
A great deal o f criticism has been made involving early anabolic steroid studies
(American College o f Sports Medicine, 1987). The studies that demonstrated no
increases in muscular strength have been criticized because o f the use o f inexperienced
participants, lack o f dietary (calories and protein) control, low-intensity training, and non
specific measuring o f strength (American College of Sports Medicine, 1987). The
studies that have demonstrated increases in muscular strength have been criticized for
low numbers o f participants, improper statistical designs, inadequate execution, and
unsatisfactory reporting o f the results (American College o f Sports Medicine, 1987). A
meta-analysis o f the studies from 1966 to 1990 performed by Elashoff, Jacknow, Shain,
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& Braunstein (1991) assessed the effects o f anabolic steroids on human muscular
strength. Thirty studies were reviewed in which subjects received more than one dose of
the anabolic steroid studied and in which changes in muscular strength were measured.
O f the 30 studies, 14 were determined to be o f poor quality for various reasons (Elashoff
et al., 1991). A ll of the studies differed in regards to the length of time o f anabolic
steroid administration, the intensities o f strength training programs, the pre-training levels
o f strength in the participants, and especially the dosages o f anabolic steroids
administered (Alen & Hâkkinen, 1987; Lombardo, 1993).
The weight training experience of the participants is an important factor to
consider (Lombardo, 1993). Alen and Hâkkinen (1987) explained that anabolic steroids
do not accelerate the physical development o f athletes in the very early phase of strength
training because the strength training itself is enough of a stimulus to produce substantial
gains during that phase. Inexperienced weightlifters w ill make large gains at the
beginning o f any weight training program; these large gains are not significantly
increased by anabolic steroids in the early part o f their training (Lombardo, 1993).
Blue and Lombardo (1999) stated that at therapeutic doses, anabolic steroids do
not enhance muscle strength or athletic performance. Endogenous testosterone
production is depressed, and the net effect is negligible (Blue & Lombardo, 1999).
According to Percy (1978), Lamb (1984 and 1989), Taylor (1987), Elashoff et al. (1991),
and (Wagner, 1991) one obvious flaw with past anabolic steroid research, is that the
amount o f the anabolic steroids administered in most clinical studies has been well below
the massive doses taken by athletes. The dosages o f anabolic steroids taken by most
athletes are 10 to 200 times greater than normal therapeutic doses, in an attempt to
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maximize the anabolic effects (Street et al., 1996; Blue & Lombardo, 1999). Casaburi,
Storer, and Bhasin (1996) stress that the doses of anabolic steroids used in studies are low
considering, 1) all testosterone derivatives are less potent than testosterone; 2)
approximately 7mg o f testosterone are produced daily in healthy males; 3) the absorption
o f oral anabolic steroids is erratic and incomplete; 4) some of the orally administered
anabolic steroid is metabolized by the liver during the first pass through. Taylor (1987)
and Wilson (1988) noted that scientific research also does not involve the administration
o f anabolic steroids in the stacking and cyclical fashions utilized by many athletes. Lamb
(1989) and Wagner (1991) stated that it is medically unethical to administer anabolic
steroids in the dosages used by athletes. Very few definitive, controlled clinical trials
with supraphysiological doses o f anabolic steroids have been conducted (Bardin,
Swerdloff, & Santen, 1991).
Further research has also been hampered by the problems o f conducting a true
double-blind study (Lamb, 1989; Wagner, 1991). A double blind study to investigate the
effects o f anabolic steroids would be ideal, but many athletes can recognize when they
are on the anabolic steroid compared to the placebo (Lamb, 1989). In a study by Freed,
Banks, Longson, and Burley (1975), all thirteen participants guessed correctly when they
were on the steroid and the placebo portions o f the study. Lamb (1984) and Taylor
(1987) concluded that because o f the lack of a satisfactory placebo and the usually low
steroid doses that are used in research studies, great care should be considered when
evaluating scientific evidence that deals with anabolic steroid use in athletes. The studies
that appear in the literature are o f limited value in assessing the effects o f the drugs used
(Fahey & Brown, 1973; Taylor, 1987).
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Studies that Found Ergogenic Benefits
Papanicolaou and Falk (1938) were some of the first to note that androgenic
hormones (testosterone propionate) have a stimulating effect on the muscles, producing
hypertrophy after long-term administration. During the 1960’s and 70’s, researchers
attempted to perform studies that investigated the effects of anabolic steroids on muscle
strength and body composition (Taylor, 1987). The difficulties encountered during this
process have already been mentioned. In most studies in which trained athletes took
steroids in relatively low doses for short periods of time and also used weight training
and proper diet, a significant increase in skeletal muscle mass and muscle strength was
noticed in many subjects (Taylor, 1987). Despite the problems with the scientific data, it
is commonly accepted on the part o f athletes, coaches, sport physicians, and the public
that anabolic steroids improve athletic performance (Bardin et al., 1991). While many o f
the studies were not double-blinded or placebo controlled, it has to be concluded that
anabolic steroids, in high doses combined with heavy resistance training w ill result in
increased body weight and muscle size (MacDougall, 1983).
Johnson and O’Shea (1969) studied the effects o f an anabolic steroid on strength
development. In what was planned to be a double blind study (only twelve men were
w illing to take the steroid and thus became the experimental group), twelve pairs of
participants were fed protein supplements and trained with weights for six weeks. During
the first three weeks, all participants were treated identically with the same weight
training program and protein supplements. During the last three weeks o f the study, the
experimental group received 10 mg/day o f methandrostenolone. The results indicated
that both dynamic and static strength and body weight increased significantly in the
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that both dynamic and static strength and body weight increased significantly in the
experimental group. The increased body weight occurred with no significant changes in
subcutaneous adipose tissue, leading the investigators to believe that the weight gained
was lean body mass and not body fat. Surprisingly, maximum oxygen uptake increased
significantly, even though the training program was not designed to promote
cardiovascular fitness. The researchers concluded that the combination o f anabolic
steroids, high protein intake, and heavy weight training accelerated protein synthesis and
increased static and dynamic muscle strength and body weight.
O’Shea and Winkler (1970) studied the effects of an anabolic steroid
(oxandrolone) on the physical factors involved with sport-specific training in highlyadvanced swimmers and weightlifters. Double blind testing was not used for this study
because o f the small number o f participants. During the first six weeks o f the elevenweek study, subjects were given 10 mg/day o f oxandrolone (treatment period) and a
protein supplement; during the final five-week washout period, no anabolic steroids were
administered. The results o f this study indicated that body weight increased in all
participants. An increase in protein utilization was also demonstrated in eight of the
eleven participants. In the group of swimmers, no improvement was noted in
performance (swimming speed), while muscle strength improved dramatically in the
group of weightlifters. The investigators concluded that muscular strength is increased
when anabolic steroids are combined with a high protein diet and heavy weight training.
The investigators also considered that because the weightlifters knew they were receiving
anabolic steroids, the degree to which the strength increases can be attributed to the
steroids rather than psychological effects cannot be distinguished.
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Ward (1970) investigated the effects o f an anabolic steroid (10 mg/day of
methandrostenolone), in conjunction with heavy weight training on maximum strength
(standing press, squat, and bench press), maximum oxygen uptake, lean body mass, and
blood volume in one experienced weightlifter. Maximum strength in all three exercises
increased significantly (35 lbs, 12.73% in the standing press, 50 lbs, 10.75% in the squat,
and 35 lbs, 9.09% in the bench press). Maximum oxygen uptake (in the absence of
cardiovascular training) increased 15.66% when measured in aerobic capacity, and
12.97% when measured in aerobic power. Lean body mass increased 18 lbs, while body
fat decreased 9 lbs (4%). Blood volume was not changed. The author concluded that
anabolic steroids may be beneficial in increasing muscle strength, lean body mass, and
possibly aerobic endurance.
O’Shea (1971) studied the effects o f an anabolic steroid on the muscular strength
levels of twenty male weightlifters. The participants were divided into a placebo and a
steroid group (10 mg/day of methandrostenolone); the diets of all participants were
augmented with a protein supplement. The weight training program employed in this
study was identical for all participants, and was noted as being very intense. The results
o f this study indicated that maximum bench press and squat strength increased
significantly in the group who received anabolic steroids. Body weight in the steroid
group also increased significantly. When a skinfold measurement was taken at the waist,
no increase was noted, indicating the weight gained was lean body mass, and not adipose
tissue. The researchers concluded that anabolic steroids do increase dynamic strength in
competitive athletes, but that this is very dependant on the type and the quality o f both
the training (heavy weightlifting) and the diet (high protein) consumed.
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The physiological effects o f the anabolic steroid, methandrostenolone, were
studied by Ariel in 1972. In the first seven weeks of a fifteen-week study, the six
participants trained with weights five days a week (training period). From the eighth to
the eleventh week o f the study, all participants were given a placebo and were told it
contained 10 mg o f methandrostenolone (placebo period). From the twelfth to the
fifteenth week o f the study, three o f the participants received 10 mg of
methandrostenolone (experimental group), while the other three participants continued to
receive the placebo (anabolic steroid period). Significant increases in muscle strength
were noticed in the experimental group between the placebo period and the anabolic
steroid period. The investigator concluded that the experimental group was able to exert
greater maximum muscular contractile force during the anabolic steroid period when
compared to the placebo period and to the control group, whose progress did not increase
significantly.
The effects of the anabolic steroid methandrostenolone on strength and aerobic
capacity were studied by Bowers and Reardon (1972). Eighteen weightlifters
volunteered for this six-week study, and were divided into an experimental (steroid) and a
control (placebo) group. A ll subjects received daily protein supplementation; the steroid
group received 10 mg/day o f methandrostenolone for the last twenty-one days o f the
study. The results of the study showed that the experimental group significantly
increased strength in the bench press and squat, body weight and bicep and forearm girth
over the control group. No increases were seen in aerobic capacity.
Johnson, Fisher, Silvester, and Hofheins (1972) studied the effects o f an anabolic
steroid (methandrostenolone) on muscular strength, body weight, oxygen uptake and
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spermatogenesis. A ll subjects began an identical seven-week weight-training program; at
the end of the fourth week, 24 o f the 31 subjects were randomly placed into either the
control (placebo) group, or the treatment (10 mg/day o f the anabolic steroid) group. In
addition, all subjects supplemented their diet with a protein supplement. The results
showed no significant increase in maximum oxygen uptake, and no changes in sperm
count. In the treatment group, strength increased and the gains in body weight were
significant over the placebo group. The investigators concluded that anabolic steroid
supplementation does significantly improve muscle size and strength when accompanied
with a high protein diet and intensive weight training.
Ward (1972) investigated the effects of an anabolic steroid on maximum strength
and lean body mass. Sixteen healthy male weight trainers volunteered for the five-week
study. The participants were divided into an experimental group (10 mg/day of
methandrostenolone) and a placebo group. The results indicated that the experimental
group improved in maximum strength and gained more lean body mass than the control
group. The experimental group had a significant increase in body mass, and a significant
reduction in body fat, with no increase in body weight above the control group. The
author concluded that the use o f anabolic steroids may produce significant increases in
strength and lean body mass in athletes involved in a heavy weight training program
beyond what would result from heavy weight training alone.
Ariel (1973) investigated the effect on an anabolic steroid on maximum skeletal
muscle contractile force. Six male weightlifters volimteered for this eight-week double
blind study. The participants were divided into an experimental group (10 mg/day of a
placebo from weeks two through four and the steroid from weeks four through eight) and
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a placebo group (placebo administered weeks two through eight). The results indicated
that the experimental group was able to exert greater maximum muscle contractile force
during the anabolic steroid period when compared to the placebo period and the control
group, who did not significantly improve performance. The rate of progress of the
experimental group was higher during the anabolic steroid period when compared to the
control group.
Brown and Tait (1973) interviewed a number of athletes who were selfadministering various dosages and types of anabolic steroids. A ll reports of strength and
weight increases were subjective and reported by the athletes themselves. The weight
gained was highly variable; three athletes gained no weight, while one gained 40 and
another SOlbs. Seven athletes gained strength, while two did not. Most o f the athletes
who reported strength gains said they were dramatic; one increased his maximum deadlift
110 lbs, another gained 90 lbs on his maximum squat. It was concluded that anabolic
steroids may increase strength development when accompanied by a healthy diet and a
heavy weight training program.
Ariel (1974a) investigated the prolonged effects of an anabolic steroid on muscle
strength following cessation of treatment and a 15-week detraining period. College-aged
male participants were divided into two groups, the experimental group who received 15
mg o f methandrostenolone daily for four weeks, or the control group who received
nothing. Following the four weeks o f anabolic steroid treatment, the drug was removed
and weight training ceased (15 weeks o f detraining). Maximum strength was tested in
the bench press, military press and the squat in all participants. Following the 15 weeks
o f detraining, muscle strength was tested again in all participants. In the bench press, the
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experimental group lost a not statistically significant 6.6 kg o f strength, while the control
group lost a significant 19.9 kg. In the military press, the experimental group lost a not
statistically significant 4.76 kg o f strength, while the control group lost a significant 9.52
kg. In the squat, the experimental group lost 8.44 kg (not statistically significant), while
the experimental group lost 15.19 kg, which again was significant. This study indicated
that participants who were involved in strength training without anabolic steroids lost a
significant amount o f strength following detraining, while the participants who trained
with anabolic steroids were better able to maintain their strength levels following
detraining.
Ariel (1974b) investigated the residual effects o f anabolic steroid administration
on muscular force following cessation. Ten male weight lifters were divided into two
groups, one who received the anabolic steroid (15 mg o f methandrostenolone daily) first,
followed by an identical placebo (Group 1), or one who received the placebo first, then
the anabolic steroid (Group 2). A ll participants underwent an identical weight training
protocol. The results indicated that anabolic steroids enhanced muscular strength, and the
rate of increase o f muscular strength. Following the administration o f the anabolic
steroid, there was a dramatic decrease in the muscular strength gained. Group 1 showed
significant strength gains while using the anabolic steroid, but following cessation of the
steroid, no significant gains in muscular strength were found. During the placebo period
in Group 2 (the first part o f the study), significant gains in three o f the four weight
training exercises were demonstrated; during the anabolic steroid period for Group 2,
significant gains in muscular strength were seen in all participants in all weight training
exercises.
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O’Shea (1974) studied the effects of stanozolol (an anabolic steroid) on adrenal,
liver, and muscle function in men. Eighteen weightlifters were equally divided into two
groups, a treatment (stanozolol) and a placebo group, for the five-week study.
Participants in the treatment group were given 8 mg/day o f stanozolol; all participants
supplemented their diets with a protein supplement and participated in an identical weight
training program. When the biochemical data was evaluated, no significant alterations
were noted in regards to adrenal, liver, or muscle function. When body weight and
muscle strength were measured, the treatment group increased significantly in regards to
muscle strength, but the body weight gained was not significant. The investigator
theorized that anabolic steroids, when supplemented with a high protein intake and an
intense weight training program, promote significant increases in dynamic muscular
strength.
The purpose o f the Stamford and Moffatt (1974) study was to approximate the
actual conditions under which athletes use anabolic steroids. The controlled conditions
included the administration o f more than the recommended dosage o f anabolic steroids, a
high protein diet, and an intense weight training program. Twenty-four male
weightlifters all underwent an identical weight training program, for four weeks. After
the initial four week period, the participants were divided into four groups. Group 1
received 20 mg o f methandrostenolone and a protein supplement daily. Group 2 received
an identical placebo and a protein supplement. Group 3 received only the protein
supplement, and Group 4 received nothing, serving as the control. The results indicated
that Group 1 had significant increases in bench press strength, static strength, and body
weight compared to Groups 2,3, and 4. It was concluded that 20mg o f
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methandrostenolone (a dose higher than the recommended therapeutic dose) can
effectively accelerate strength and muscle mass gains in experienced weightlifters.
Freed, Banks, Longson, and Burley (1975) tested thirteen male weightlifters, who
ingested a high protein diet, exercised regularly, and took either 10 or 25 mg/day of
methandrostenolone or a placebo, in a crossover design, to see what effect it had on
athletic performance. The athletes chose a low dose (10 mg/day) or a high dose (25
mg/day) of methandrostenolone and were tested for two consecutive six-week sessions,
with the anabolic steroid and the placebo given in a random order. The investigators
insisted on some previous weightlifting experience, and only experienced weightlifters
were included in the study, this was because when inexperienced participants begin a
weight training program, the initially rapid strength gains caused by neuromuscular
adaptations (Hâkkinen, 1994) would theoretically mask any benefits that would occur due
to anabolic steroid supplementation. Athletic performance was measured as percentages
of maximum weight lifted in six strength training exercises, including the squat and the
bench press. Improvements in strength were significantly greater during the anabolic
steroid supplementation period than during the placebo period. Body weight also was
measured, and increased significantly during the anabolic steroid period. The weight
gain was attributed to water retention and not muscle mass. The investigators reasoned
that anabolic steroids improve athletic performance only when given in combination with
weight training and a high protein diet. It was theorized that while using anabolic
steroids, athletes are less susceptible to fatigue, allowing longer, more frequent and
harder training sessions.
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Win-May and Mya-Tu (1975) conducted a study to assess the effects of anabolic
steroids on various measures of physical fitness, including anthropometry, balance,
coordination and flexibility tests, static and dynamic strength, and cardio-respiratory
endurance. Thirty-one male university students were randomly divided into either the
anabolic steroid group, who received 5 mg/day of methandrostenolone for three months,
or the control group, who received a placebo. The results o f this investigation showed a
significant increase in the anthropometric measurements (body weight, and six body
circumferences) in the steroid group, compared to the placebo group. Static and dynamic
strength was also shown to increase in the steroid group. No increases were noted in
balance, coordination, flexibility or cardio-respiratory endurance with the administration
o f the anabolic steroid. The investigators also subjectively noted that muscle hypertrophy
resulted from the administration o f the anabolic steroid. It was concluded that anabolic
steroids have an effect on some areas of physical fimess.
Wynn (1975) cited the powerful effects o f anabolic steroids in anorexic patients.
First, an anorexic girl consumed 3000 calories and a high amount of protein daily for 10
days. Only a weak positive nitrogen balance was noticed. During the following period,
when the anabolic steroid methandrostenolone was administered, the positive nitrogen
balance increased at least threefold, and remained elevated for the 34-day administration
period. The anabolic steroid period was also associated with a significant weight gain.
When the anabolic steroid was removed, the positive nitrogen balance ceased and no
further weight gain was noticed. Another case o f the strong effects o f anabolic steroids
involved a teen-age boy who was also anorexic. This time on a 4000 calorie a day diet,
containing high quantities o f protein, a modest positive nitrogen balance was noticed.
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When the anabolic steroid methandrostenolone was administered, the magnitude of the
positive nitrogen balance increased threefold* and remained elevated for the whole period
o f anabolic steroid treatment. Again, the positive nitrogen balance associated with the
anabolic steroid resulted in significant weight gain. When the anabolic steroid treatment
ceased, the weight gain halted and nitrogen balance returned to zero.
Hervey (1975) and (1976) studied the effects o f the anabolic steroid
methandrostenolone on body composition and muscular strength in untrained men.
Using a crossover, double-blind design, the participants were randomly given the steroid
(100 mg/day) or a placebo. The two treatment periods (weight training and placebo or
weight training and steroid administration) were separated by five weeks of abstinence
from weight training. The results indicated that while on the steroid, the participants
gained significantly more weight than during the placebo administration period. On the
basis of total body potassiiun measurements and the significant increase in thigh muscle
mass width, the weight gained was determined to be in the lean body compartment. The
increases noticed in muscular strength were not significantly different during either
steroid or placebo administration. It was concluded that the widely held belief that
anabolic steroids cause weight gain (lean body mass gain) in young men undergoing
weight training is true, although, the belief that anabolic steroids improve strength and
performance was not shown to be true during this study.
Studies with anabolic steroids since 1975 have tended to be more carefully carried
out, better controlled, and more sophisticated (George, 1988).
Tahmindjis (1976) studied the effects o f self-administration o f anabolic steroids in
twenty male weightlifters. In all participants, body weight was shown to increase.
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ranging from 1.5 to 13.2% o f body weight, with an average o f a 5.7% increase. Muscle
strength was also shown to increase dramatically when the participants were using the
anabolic steroid compared to when they were not. The smallest improvement in
muscular strength (combination o f bench press and squat strength) noticed while using
anabolic steroids was 100% greater than the improvement without anabolic steroids; the
largest improvement was 380%, the average improvement was 195%.
Hervey, Knibbs, Burkinshaw, Morgan, Jones, Chettle, and Vartsky (1981) studied
the effects o f methandienone on muscular strength and body composition in competitive
weightlifters. A 100 mg/day dose (a dose sometimes quoted as being as high as some
athletes take) o f the anabolic steroid or an identical placebo were administered for six
weeks, and then alternated in a double-blind, crossover fashion. During the steroid
treatment period, body weight, total body potassium and nitrogen, muscle size, and leg
strength increased dramatically when compared to the placebo period.
Alèn, Hâkkinen and Komi (1984) investigated the changes in body composition,
muscle fiber characteristics, and isometric and dynamic force output o f the leg extensor
muscles in five experimental (self-administration of very high doses o f anabolic steroids)
and six control (no anabolic steroids) power athletes during twenty-four weeks of a
strength training program. Following the twenty-four weeks o f anabolic steroid selfadministration, a six-week period without any anabolic steroids followed, and the same
measurements were taken again. The results indicated that anabolic steroids significantly
increased body mass (average o f 11.25 pounds), lean body mass (average 17 pounds) and
mean muscle fiber area in the experimental power athletes, while no significant changes
were noted in any o f the measurements in the control power athletes. Maximum
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isometric force also significantly improved in the experimental group. During the six
weeks without anabolic steroids, significant changes were noticed in the experimental
power athletes in body composition and force output. Significant increases were seen in
dynamic and isometric force, while body mass was significantly decreased. The
researchers noted that this decrease in body mass could reflect the elimination of fluid
that was retained during the anabolic steroid period. An interesting point that was noted
during this study was that during the first six weeks, similar increases in all
measurements were noticed in both groups. While the study continued, the increases in
the experimental group far surpassed those o f the control group. The researchers
concluded that the achievements in muscular strength might depend on the duration of
the steroid use and the training methods utilized.
Alèn and Hâkkinen (1985) performed a case study on an elite bodybuilder who
self-administered extremely high doses o f anabolic steroids over a one year period.
During one twenty-six and one twenty-four week steroid self-administration cycle
(separated by four weeks without anabolic steroids) total body mass, lean body mass,
mean fiber area o f the vastus lateralis muscle, total thigh girth, and maximum leg
extension strength all increased significantly. No changes were noticed in maximum
oxygen uptake or maximum anaerobic power. It was concluded that strength training
combined with the use o f extremely large doses o f anabolic steroids might have increased
protein synthesis, which resulted in muscle hypertrophy. The authors explained that low
receptor affinities characterize most o f the anabolic steroids so that high doses must be
administered to obtain anabolic effects greater than those due to a natural training
stimulus.
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Forbes (1985) analyzed four o f his own subjects, along with ten studies that
measured changes in lean body mass before and after anabolic steroid administration.
His four subjects demonstrated significant increases in lean body mass, and decreases in
body fat during anabolic steroid administration. It was determined that the magnitude of
the increases in lean body mass were related to the total amount o f the anabolic steroid
administered. With low doses o f anabolic steroids, increases in lean body mass were
only one to two kilograms. When large doses of anabolic steroids were administrated the
results indicated a progressive increase in lean body mass. Using the available
information, the author developed a dose-response curve. The x-intercept of the
regression line for the dose response curve was 2535 mg o f total steroid dose; this
represented the threshold for a significant effect on lean body mass. Forbes (1985) also
calculated that between the ages of 13 to 20, males have produced 15,330 mg of
testosterone more than females (6mg/day x 365 days x 7 years). This number represents
the upper lim it of the dose response curve. The corresponding upper lim it o f lean body
mass gain was calculated to be 19 kilograms.
Hâkkinen and Alen (1986) investigated the effects o f self-administration of
multiple anabolic steroids and strength training on the physiological performance and
physical health o f an elite bodybuilder. This study was noted as being o f great value in
assessing the effects o f anabolic steroids in athletes. It investigated the self
administration of multiple anabolic steroids, in the dosages often taken by athletes,
addressing two o f the major criticisms of anabolic steroid research. The results o f this
study indicated an extraordinary increase in serum testosterone during anabolic steroid
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supplementation. This rise in testosterone was associated with large gains in fat-free
mass, mean muscle fiber area, and maximal strength.
Alèn and Hâkkinen (1987) investigated the effects o f six months of self
administered anabolic steroid supplementation on serum hormone levels and maximal
force development in four top-level Finnish strength athletes (experimental group). Five
other top-level Finnish strength athletes who did not supplement their training with
anabolic steroids served as a control group. The investigators commented on the need for
a study o f this design, examining strength development in elite strength athletes who are
self-administering very high doses of multiple anabolic steroids while involved in heavy
prolonged weight training. A ll participants were also given a protein supplement. The
results indicated that total body mass and lean-body mass increased significantly (an
average o f 12 and 22 pounds, respectively) in the experimental group. Muscular strength
and mean serum testosterone also increased significantly in the experimental group. No
significant changes were seen in the control group.
Griggs, Kingston, Jozefowicz, Herr, Forbes, and Halliday (1989) investigated the
effects o f testosterone on muscle mass and protein synthesis in the absence of a weighttraining program in nine normal male participants. The participants were administered 3
mg/kg/week of testosterone enanthate for twelve weeks. Muscle mass (estimated by
creatinine excretion) increased in all nine participants on average 20 %. Muscle protein
synthesis was also shown to increase on average 27 % in all participants. No significant
increases in muscle fiber diameter were seen. The investigators concluded that
testosterone increases muscle mass by increasing muscle protein synthesis.
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Friedel, Dettori, Hannan, Patience, and Plymate (1991) examined the effects of
supraphysiological doses o f anabolic steroids on body composition and muscular
strength. Thirty male participants were divided into one of four groups who received
either, (1) 100 mg/week of testosterone enanthate (ser/ed as a replacement dose
comparison), (2) 300 mg/week testosterone enanthate, (3) 100 mg/week nandrolone
decanoate, or (4) 300 mg/week nandrolone decanoate, for six weeks. The results
indicated that body weight significantly increased in groups 2 ,3,and 4, but not group 1.
No changes were found in skinfold thickness or percent body fat, therefore, the weight
gained was theorized to be lean body mass. Muscular strength significantly increased in
all groups except in group 1. The greatest improvements in strength were noticed in
group 4. Serum testosterone increased threefold in group 2, while no significant increase
was noted in group 1. The researchers concluded that high doses o f anabolic steroids
(groups 2,3, and 4) produced significant increases in body weight (lean body mass), and
muscular strength. In group 1, the absence o f any changes, and the maintenance of
normal serum testosterone levels, indicated that 100 mg/week was the same as a
replacement dose o f testosterone.
A study conducted by Forbes, Porta, Herr, and Griggs (1992) looked at the
changes in body composition caused by testosterone administration. Seven untrained
subjects were given 3 mg/kg o f intramuscular testosterone enanthate for a total of twelve
weeks. The participants were told to stick to their normal daily routine (diet and
exercise). Lean body mass increased progressively throughout the study. The average
increase in lean body mass was 7.5 kg (range 5.7 - 11.9 kg). The average change in body
weight was 4.1 kg, thus, on average, 3.4 kg o f body fat was lost during the study. The
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participants retained the increased lean body mass for at least five to six months
following the study, demonstrating that the increases in lean body mass are maintained
following cessation of the steroid administration. The investigators concluded that the
changes in body composition were the result of the testosterone supplementation.
Urinary creatinine was measured and indicated that most, if not all, of the increased lean
body mass was muscle tissue.
Welle, Jozefowicz, Forbes, and Griggs (1992) investigated the effects of
testosterone on basal metabolic rate (BMR) and lean body mass in normal men and men
with muscular dystrophy, for periods lasting three and twelve months. The participants
were divided into a control (no anabolic steroid) and experimental (testosterone
injections) group in both the normal men and men with muscular dystrophy. No
significant changes were demonstrated in either BMR or lean body mass in the control
groups. The testosterone injections significantly increased plasma testosterone levels for
the study period (average threefold increase). In normal men, after three months, BMR
was shown to increase 7%, while men with muscular dystrophy demonstrated a 13%
increase in BMR; after twelve months, the BMR had still increased a total o f 9% in men
with muscular dystrophy. Lean body mass (using urinary creatinine excretion) also
increased significantly (approximately 10.5%) after three months, and remained elevated
after twelve months. The men with muscular dystrophy who were treated with
testosterone lost body fat (average 6 kg) during the treatment, while those who received
the placebo actually gained body fat during the study.
Bhasin, Storer, Berman, Callegari, Clevenger, Phillips, Bunnell, Tricker, Shirazi,
and Casaburi (1996) looked at the effects o f supraphysiologic doses of testosterone on
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muscle size and strength in normal men. The men were randomly assigned to one of four
groups, a placebo and no exercise group, a placebo and exercise group, a testosterone and
no exercise group, and a testosterone and exercise group. The participants received either
600 mg/week o f testosterone enanthate or a placebo for 10 weeks. The 600 mg/week
dose o f testosterone enanthate is six times higher than the usual replacement dose
administered to hypogonadal men. Before and after the treatment, body composition (fat
free mass) using underwater weighing, muscle size using magnetic resonance imaging,
and upper and lower body strength using the bench press and squat, respectively, were
measured. The intake o f energy and protein and the exercise (strength training) program
were standardized in an attempt to control for some o f the factors that have been
criticized in many o f the previous studies conducted on the effects o f anabolic steroids on
performance. Free and total testosterone increased significantly in the two groups who
received testosterone, but not in either placebo group. The men in the testosterone and no
exercise group had a significant increase in body weight, coupled with a 3.2 kg average
increase in lean body mass. The testosterone and exercise group had an average increase
o f 6.1 kg in body weight and an average increase in lean body mass o f 6.1 kg, indicating
that the weight gained was lean body mass. No significant changes were seen in either of
the placebo groups for body composition. When muscle size was analyzed, the mean
cross sectional area o f the arm and leg muscles in the placebo groups did not significantly
change. Both o f the groups that received testosterone had significant increases in cross
sectional area o f the arm and leg muscles, with the testosterone and exercise group
greater than the testosterone and no exercise group. The men in the testosterone and no
exercise group had significant increases in maximum squat and bench press strength of
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19% and 10%, respectively, almost identical to the increases seen in the placebo and
exercise group. In the testosterone and exercise group, the increases in maximum squat
and bench press strength were 38% and 22%, respectively, twice as great as the
testosterone and no exercise and the placebo and exercise groups. The investigators
concluded that supraphysiological doses of testosterone increase lean body mass, muscle
size and strength in normal men.
Bhasin, Storer, Berman, Yarasheski, Clevenger, Phillips, Lee, Bunnell, and
Casaburi (1997) investigated the effects o f replacement doses of testosterone on lean
body tissue and muscle size in hypogonadal males while on a protein and energy
controlled diet. Participants were given testosterone enanthate (100 mg/week) for 10
weeks. Body weight increased on average 4.5 kg, with lean body mass increasing
approximately 5 kg. Cross-sectional area of the triceps and quadriceps, as measured by
magnetic resonance imaging, both increased significantly. Muscle strength also
increased approximately 11 kg in the bench press, and 31 kg in the squat, even though the
participants were not involved in a strength training program. The investigators
concluded that testosterone replacement in hypogonadal men increases lean body mass
and muscle size.
Kadi, Erikkson, Holmner, and Thomell (1999) found that the mean area o f the
muscle fibers in high-level power athletes using anabolic steroids were larger than in
similar athletes who did not use anabolic steroids. The researchers concluded that the use
o f anabolic steroids and strength training cause an increase in the size o f the muscles both
by hypertrophy and hyperplasia. It was proposed that anabolic steroid use causes the
activation o f satellite cells, resulting in an increase in the number o f muscle fibers.
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Sattler, Jaque, Schroeder, Olson, Dube, Martinez, Briggs, Horton, and Azen
(1999) investigated the effects on body weight, lean body mass, muscle cross-sectional
area, and muscle strength during nandrolone decanoate supplementation, combined with
weight training in men with human immunodeficiency virus. Participants were divided
into either a group who received the anabolic steroid (600 mg/day) (A), or a group who
received the anabolic steroid (600 mg/day) combined with weight training (B). Body
weight rose on average 4.0 kg and 3.2 kg, and lean body mass (measured by dual energy
x-ray absorptiometry) increased on average 5.2 kg and 3.9 kg in Group B and A,
respectively. Muscle cross-sectional area o f the thigh, quadriceps and hamstrings,
measured by magnetic resonance imaging, increased significantly in both groups.
Muscle strength also increased significantly in both groups, with more significant
increases in Group B.
Taylor, Brooks and Ryan (1999) demonstrated that short-term administration of
anabolic steroids (nandrolone decanoate) resulted in increased mass and contractile force
in immobilized and nonimmobilized rabbit skeletal muscle. The authors concluded that
anabolic steroid administration would result in muscle hypertrophy without weight
training or a high protein diet.
It has been concluded that in inexperienced weightlifters, neither total and lean
body mass, muscular strength, nor aerobic strength are likely to be influenced by
administration o f therapeutic doses o f anabolic steroids in the absence o f an exercise
program that promotes anabolism (Wright, 1980). Even when anabolic steroids are
administrated during strength training and protein supplementation, strength and body
weight may not increase more than with training alone (Wright, 1980: Lamb, 1984 and
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1989). For experienced weightlifters, therapeutic doses o f anabolic steroids appear to
enhance the normal increases in body mass that occur with weight training (Wright,
1980; Lamb, 1984 and 1989). The effects on body composition are not as clear as the
effects on body weight because o f factors such as lack o f dietary control, different
anabolic steroids and dosages, different training programs and durations, and individual
differences in body composition and metabolic rates (Wright, 1980).
Haupt and Rovere (1984) concluded that anabolic steroids w ill consistently show
increases in muscular strength if the following criteria are met: 1) anabolic steroids are
administered to athletes who have trained with weights immediately before
administration, and who continue weight training during the treatment period; 2) athletes
maintain a high protein diet; and 3) strength changes are measured by the one repetition
maximum (IRM ) technique for the exercise that the athlete trains.

Studies that Found No Ergogenic Benefits
While most believe that anabolic steroid supplementation increases muscular size
and strength, and total and lean body mass, not every study has come up with those
conclusions.
Samuels, Henschel, and Keys (1942) first investigated the effects o f anabolic
steroids on a measure o f muscular performance, grip strength. Participants ingested SO
mg of methyl testosterone daily. No improvements in grip strength, beyond a training
effect, were noticed in the participants. The authors concluded that no strength
improvements are obtained with supplementation o f SOmg/day o f methyl testosterone.
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The effects o f an anabolic steroid (Nibal), either taken alone or in combination
with exercise (non-weight training workouts), were studied by Fowler, Gardner, and
Egstrom (1965). Participants were placed into one of four groups, a placebo group, an
anabolic steroid group, a placebo and exercise group, and an anabolic steroid and
exercise group. O f interest to the investigators were the effects o f the anabolic steroid on
strength, physical working capacity, a series of anthropometric measurements, and motor
performance. The results o f this study showed that there were no significant differences
in any of the measurements between the groups that did not exercise and who received
either the placebo or the anabolic steroid. The only improvements in performance were
noted in both exercising groups, with no significant differences between the two groups.
The investigators concluded that anabolic steroid supplementation in normal doses does
not increase muscle size or strength, and would be o f no use to athletes.
Casner, Early, and Carlson (1971) studied the effects o f an anabolic steroid
(stanozolol) on body weight, body composition, and muscle strength in normal,
untrained, young men. Twenty-seven men were placed into one o f four groups; steroid
and normal daily activity, steroid and weight training, placebo and normal daily activity,
and placebo and weight training. The participants in the two steroid groups received 2
mg o f stanozolol three times a day on days 1-21 and 28-49 o f the 56-day experiment.
The results indicated no significant increases in muscle strength in any group. An
increase in body weight was noted for both groups receiving the anabolic steroids, but
was theorized to be fluid retention. The investigators concluded that anabolic steroids
cause an increase in body weight, however, the weight gained may have been due to fluid
retention and not muscle mass and therefore was o f no benefit to athletes.
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In a study conducted by Fahey and Brown (1972), the effects o f an anabolic
steroid (nandrolone decanoate) on strength, body composition, and endurance were
studied in college aged males with limited weightlifting experience. Participants were
placed into either the treatment group (1 mg/kg o f nandrolone decanoate at week two,
five, and seven of a nine week program) or the placebo group. While the treatment group
gained more weight, and increased maximum muscular strength compared to the placebo
group, none o f the differences were statistically significant. It was concluded that the
anabolic steroid, in the usual recommended dosage, did not enhance strength, lean body
mass or aerobic capacity. The investigators did acknowledge that the results could have
been due to the fact that adequate protein intake (protein powder supplementation) seems
to be necessary for anabolic steroids to be effective.
The effects o f an anabolic steroid on strength development, anthropometric
measurements, body weight, and aerobic power were investigated by Stremme, Meen,
and Aakvaag (1974). During the eight-week experiment, twenty-one men were divided
into a treatment group which received the anabolic steroid at a dosage o f 75 mg/day for
the first four weeks, and 150 mg/day for the last four weeks, or a placebo group.
Throughout the experiment, all participants were given a protein supplement and
underwent the same weight training program. The results indicated that for the strength
development and anthropometric measurements, the steroid group showed gains over the
control group, but the differences were not statistically significant (the only significant
increase over the control group was in right thigh circumference). The steroid group
showed no improvement in aerobic power, and actually showed a slight decrease, while
the placebo group showed an increase in aerobic power. It was concluded that this
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anabolic steroid (mesterolone) does not improve muscular strength or aerobic power in
normal healthy men.
Golding, Freydinger, and Fishel (1974) examined the effects o f an anabolic
steroid (methandrostenolone) and a protein supplement on muscle size, strength, and
body composition in male weightlifters. During a twelve-week study, 40 participants
were divided into one o f four groups, a protein and no steroid group, a steroid and no
protein group, a steroid and protein group, and a no steroid and no protein group. A ll
subjects were told that they were taking anabolic steroids and a protein supplement. The
anabolic steroid groups received 10 mg/day o f methandrostenolone. The type, frequency,
and intensity o f training were not controlled for; all subjects maintained their normal
training protocol. No significant differences were found between the groups in skeletal
measurements, body weight, body composition, static strength, or dynamic strength
measured with the bench press and arm curl. It was concluded that strength athletes
supplementing their training with 10 mg/day of methandrostenolone, either in the
presence or absence o f additional protein, did not increase body weight, muscular size or
strength compared to a placebo.
Loughton and Ruhling (1977) investigated the effects o f an anabolic steroid
(methandrostenolone) and protein supplementation on cardiovascular endurance and
muscular strength while participating in a seven-week endurance and weight training
program. Twelve males (six trained athletes, and six untrained non-athletes) were
divided into one o f four groups, a trained steroid group, an untrained steroid group, a
trained placebo group, and an untrained steroid group. The participants in the steroid
groups received 10 mg of the steroid daily for the first three weeks and 5 mg of the
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steroid daily for the last three weeks; all participants received additional protein
supplementation. Again, no significant differences were observed in any o f the four
groups for any o f the factors that were measured (strength, oxygen uptake,
anthropometric measurements) with the exception o f body weight and bench press which
increased significantly in both steroid groups. The investigators concluded that anabolic
steroid administration resulted in no significant changes in muscle size or strength, or any
aerobic adaptations to exercise beyond those found with normal training.
Crist, Stackpole, and Peake (1983) studied the effects o f anabolic steroids on
neuromuscular power and body composition in nine (including one woman) experienced
weightlifters, receiving protein supplementation. Experienced weightlifters were used in
this study because novice weightlifters might have gained strength so rapidly from weight
training alone that any results from anabolic steroid administration may have been
masked. A ll subjects were randomly assigned to one o f three groups and were given the
three treatments (1 ml o f placetx), 100 mg/ml testosterone cypionate, and 100 mg/ml
nandrolone decanoate) in a double blind, crossover fashion. No significant differences
were seen in seven o f the ten peak torque measurements obtained from an isokinetic
dynamometer. Mean lean body mass and body fat were also unaffected by administration
of either anabolic steroid. The investigators concluded that anabolic steroids do not
produce any signiflcant changes in body composition or neuromuscular power. The
investigators theorized that the dosage or duration o f steroid administration might have
been inadequate to produce any significant improvements in the performance
measurements o f this study.
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While the difficulty in assessing anabolic steroid research has already been
discussed, Haupt and Rovere (1984) explain that the studies that did not show a
significant increase in muscle strength usually had some similarities including 1) the use
o f inexperienced weightlifters; 2) the use o f anabolic steroids other than
methandrostenolone; and 3) the use o f strength testing techniques other than one
repetition maximums (IRM) for weight lifting exercises.
Controversy as to the effects o f anabolic steroids on performance has persisted
since the 1970’s, primarily because o f misinformation from the medical and scientific
communities. From anecdotal evidence and self-administration, athletes had concluded
that anabolic steroids increased muscular size and strength, and thus improved
performance. The medical and scientific communities reached much the opposite
conclusion. Brown and Tait (1973) stated that in order to discourage steroid use, a
number of physicians and sports scientists resorted to the same scare tactics that proved
so ineffective in curbing the use o f recreational drugs. Taylor (1987) concluded that by
failing to distinguish between the effects o f anabolic steroids on trained and untrained
subjects, the scientific community came to faulty conclusions in the mid-1970 s. The
conclusions resulted in the publication of official position statements that anabolic steroid
use did not enhance athletic performance, and a halt in research on the effects o f anabolic
steroids on athletes (Taylor, 1987).
The original American College o f Sports Medicine (1977) position statement on
the use of anabolic steroids stated that administration to young, healthy people (below
age SO) in medically approved therapeutic doses, does not bring about any significant
improvements in strength, endurance, lean body mass, or body weight. Any positive
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effects come about because the users have been led to expect some positive effects
(placebo effect). Also, the report stated that there is no conclusive evidence that
extremely large doses o f anabolic steroids aid or hinder athletic performance. The
position statement concluded that because o f the failure of studies to show improvements
in muscular strength, lean body mass, or body weight after therapeutic doses o f anabolic
steroids, it is obvious that any benefits are likely to be small and not worth the health
risks (American College o f Sports Medicine, 1977).
The medical community's unconditional stance on anabolic steroids cost them
their credibility and alienated athletes (Wright, 1980; Taylor, 1987). Some excellent
examples came from (Ward, 1972) where Alan Ryan, the team physician at the
University o f Wisconsin and a former president o f the American College o f Sports
Medicine, stated that the use o f anabolic steroids is a complete waste of time and money,
and Daniel Hanley, the official doctor to the United States Olympic team, emphasized
that steroids have no effect on muscle strength. Athletes continued to believe that
anabolic steroids improved performance, and therefore used them even though the
medical community denied their role in improving performance (Taylor, 1987; Blue &
Lombardo, 1999; Taylor et al., 1999).

Anabolic Steroid and Endurance
Because anabolic steroids are used medicinally to stimulate erythropoiesis
(Wilson & G riffin, 1980; Lombardo, 1993) and treat certain anemias (Lamb, 1989),
supplementation in athletes could theoretically increase the oxygen carrying capacity o f
blood, thus increasing maximal oxygen uptake (VO2 max) (Lombardo, 1993). Wilson
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(1988) indicated that part o f the weight gain noticed while using anabolic steroids may be
increased blood volume and hematocrit.
O’Shea (1970) studied the effects of anabolic steroid administration in swimmers.
The intent o f the study was to determine the influence, if any, of anabolic steroids during
an activity that demands cardiovascular endurance and speed. Oxygen uptake, static
strength and maximum performance (speed) were measured before and after steroid
supplementation in fifteen college male swimmers. Eleven participants were divided into
either Group A (who received 10 mg o f methandrostenolone (anabolic steroid) for the
first three weeks, followed by three weeks o f placebo) or Group B (who received the
placebo for the first three weeks followed by three weeks of methandrostenolone). Four
participants served as controls in Group C. The results indicated that anabolic steroid
administration had no effect on static strength, speed, or oxygen uptake. The author
noted that all subjects in this study had very high levels of cardiovascular fitness, and
statistically significant improvements in this group o f people would be very difficult. It
was concluded that anabolic steroid treatment alone (in the absence of a high protein diet)
is ineffective in improving athletic performance.
Johnson, Roundy, Allsen, Fisher, and Silvester (1975) studied the effects of
anabolic steroids on endurance training exclusively. The investigators stated that
previous studies which showed no relationship between anabolic steroid supplementation
and changes in endurance performance involved strength training exclusively. Maximum
oxygen uptake (VOzmax), mile-run time, and body composition (skinfold thickness)
were measured in subjects who administered an anabolic steroid (or a placebo) and a
protein powder, and who participated in a supervised running program over a three-week
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period. The results o f the study showed no significant differences between the group
supplemented with anabolic steroids, and the placebo group. Thus, the investigators
concluded that anabolic steroids do not appear to have any positive effects on endurance
exercise performance or body composition (percent body fat).
Looking at the results of other studies, utilizing strength training exclusively, only
two had demonstrated an increase in maximum oxygen uptake (Johnson & O’Shea, 1969;
Ward, 1970) while many others demonstrated either no ergogenic benefit (Bowers &
Reardon, 1972; Fahey & Brown, 1973; Hervey et al., 1976; Johnson et al., 1972; Johnson
et al., 1975; Win-May & Mya-Tu, 1975), or a significant decrease in aerobic performance
(Stromme et al., 1974) following anabolic steroid administration.
In reviewing all current literature. Lamb (1989) and Haupt and Rovere (1984)
concluded that there is no scientific support to justify anabolic steroids as ergogenic aids
for improving aerobic performance over what regular aerobic training would do.
Lombardo (1993) explained that, instead, endurance athletes might administer anabolic
steroids in an attempt to improve recovery time, allowing more frequent, longer, and
higher intensity workouts.

Summary of Anabolic Steroid Research
The American College of Sports Medicine Position Stand on the Use o f AnabolicAndrogenic Steroids in Sports (1987) concluded that 1) anabolic steroids in the presence
o f an adequate diet can contribute to increases in body weight, often in the lean mass
compartment; 2) the gains in muscular strength achieved through high-intensity exercise
and proper diet can be increased by the use of anabolic steroids in some individuals; and.
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3) anabolic steroids do not increase aerobic power or capacity for muscular endurance.
Lombardo, (1993) concluded that based on the available scientific evidence and the
overwhelmingly consistent anecdotal reports of athletes, anabolic steroids w ill increase
strength and lean body mass in subjects - especially experienced weight lifters - who
perform high-intensity exercises and consume adequate diets.
To date, no controlled studies of the effects of anabolic steroids as ergogenic aids
have been performed on females (MacDougall, 1983; Lombardo, 1993). It is theorized
that even greater increases in muscle mass and strength may be noticed in females using
anabolic steroids compared to males because o f the lower circulating level of testosterone
in females (MacDougall, 1983; George, 1988; Lombardo, 1993).

Possible Mechanism of Action
While there is general agreement that anabolic steroid use enhances performance
by increasing muscular size and strength, the exact mechanism for this is unclear.
Possible mechanisms include 1) an increase in protein synthesis; 2) inhibition o f the
catabolic effects o f glucocorticoids (anticatabolic effects); 3) effects on the central
nervous system (CNS); and, 4) the placebo effect (American College o f Sports Medicine,
1987; Lombardo, 1993).

Increased Protein Synthesis
Testosterone (and anabolic steroids) is lipid soluble and readily diffuses into the
cell (George, 1988). Rogozkin (1979) demonstrated the existence o f androgen receptors
in skeletal muscle treated with anabolic steroids. Anabolic steroids combine with an
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androgen receptor in the cytoplasm in skeletal and cardiac muscles, the prostate gland,
skin, and various areas o f the brain (Wright, 1980; Lamb, 1984; Wilson, 1988;
Lombardo, 1993). The hormone receptor complex interacts with receptor sites within the
chromosomes to promote the transcription of genes, and the synthesis of messenger RNA
molecules (Wright, 1980; Lamb, 1984; Wilson, 1988; Lombardo, 1993). The increased
RNA synthesis translates into the synthesis o f more protein in the ribosomes o f the cells
(Wright, 1980; Lamb, 1984; Lombardo, 1993). Rogozkin (1979), Hough (1990), and
Blue and Lombardo (1999) suggest that anabolic steroids increase skeletal muscle actin
and myosin protein synthesis. Hough (1990) states that strength training without
anabolic steroids increases the number o f steroid receptor sites in muscle, while strength
training combined with anabolic steroids not only causes an increase in the number of
receptor sites but also saturates them.
In some tissues, testosterone is first metabolized to estradiol and 5adihydrotestosterone via the aromatase and 5a reductase enzymes, respectively, in order to
be effective (George, 1988; Bardin et al., 1991). Estradiol and 5a-dihydrotestosterone
act via the estrogen and androgen receptors, respectively (Bardin et al., 1991). Casaburi
et al. (1996) and Wilson (1988) explain that in healthy men, the androgen receptors in
most tissues are fully saturated or might even be down regulated by the androgen levels.
Thus, if androgens are to be effective in healthy men, a mechanism other than the
androgen receptor must be involved, presumably with a dose-response relationship
(Bardin et al., 1991). Since the receptors are not entirely specific, some of the effects of
supraphysiological doses o f anabolic steroids are mediated via estrogen and progestin
receptors (Bardin et al., 1991).
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Anticatabolic Effects
Anabolic steroids have their most pronounced effects in athletes who are in a
chronic catabolic state caused by training (Haupt & Rovere, 1984). It has been
hypothesized that the anabolic response in muscle could be due to a blocking of
catabolism induced by glucocorticoids binding to their receptors, slowing protein
breakdown (Wright, 1980; Haupt & Rovere, 1984; Mellion, 1984; Blue & Lombardo,
1999). Anabolic steroids competitively inhibit and displace glucocorticoids (Wright,
1980). Anabolic steroids can convert a negative nitrogen balance to a positive one, given
adequate protein intake (Haupt & Rovere, 1984; Lamb 1989). Wilson (1988) stated that
at supraphysiological doses, anabolic steroids act as glucocorticoid antagonists and
promote a positive nitrogen balance independent of the androgen receptor.
Boone, Lambert, Flynn, Michaud, Rodriguez Zayas, and Andres, (1990)
demonstrated that anabolic steroid users had significantly lower increases in creatine
kinase concentration, and a faster clearance rate following identical strength training
programs when compared to a control group who did not use anabolic steroids. This
indicates a decrease in skeletal muscle damage following exercise. Cortisol
concentration significantly increased following the strength training program in the
control group, while no significant increase was observed in the anabolic steroid group,
indicating possible suppression o f glucocorticoids. The researchers concluded that
anabolic steroid users have a diminished creatine kinase response and an altered stress
response to a bout of exercise.
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Effects on the CNS
Another theory on how anabolic steroid work deals with the androgenic (CNS)
action o f the drugs (Brooks, 1983; Lamb, 1989; Lombardo, 1993). It has been theorized
that anabolic steroids make athletes more aggressive and competitive, allowing them to
train harder, for a longer period of time, and to recover quicker from workouts. Thus, the
increases in performance are a result o f more intense and a greater volume o f training.
Hervey (1975) stated that if steroids are taken during training, fatigue is halted and that
the extra work performed during each training session provides the real ergogenic
benefits. Taylor (1987) stated that while taking anabolic steroids, athletes experience a
euphoric state with diminished fatigue, allowing them to train more intensely. Some
athletes take anabolic steroids in the hope that they w ill decrease healing time after a
muscle injury like a pull or a strain (Mellion, 1984). Although these authors (Hervey,
1975; Brooks, 1983; Taylor, 1987) have theorized that anabolic steroids work solely
through the CNS, Lamb (1989) has stated that the only evidence to support this theory
consists o f subjective sensations of greater strength gains in athletes undergoing steroid
treatment compared to a placebo.

The Placebo Effect
The placebo effect (psychological mechanisms) has been suggested as a possible
mechanism o f action for anabolic steroids by some authors (Ryan, 1981; Lombardo,
1993). Ariel and Seville (1972) demonstrated the psychological (placebo) effect of
anabolic steroid supplementation in fifteen varsity male athletes undergoing weight
training. Four months prior to the actual study, the participants exercised with weights
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five days a week. A ll participants were told o f the benefits and dangers o f anabolic
steroid use, and that some would receive the anabolic steroids during the study while
others would not. Six participants were given what they were told were anabolic steroids,
but were actually placebos. The results o f the study indicated that the strength gains
measured in four weight training exercises were greater during the placebo
(experimental) period than during the pre-placebo period. The experimenters concluded
that taking the placebo supplied the psychological benefits needed to enhance strength
gains above and beyond what would be expected. This study demonstrated the powerful
psychological effect that cannot be excluded from any ergogenic aid research. In
contrast, Wilson (1988) suggested that if this were a significant phenomenon, one would
expect the effects on muscle strength to be more consistent in the double blind studies of
athletic performance, when actually the results are inconsistent. In reality, athletes do
not care whether the improvements in muscular strength are caused by the anabolic
effects of steroids on muscle mass or psychologically induced improvements, as long as
there are improvements (Lamb, 1989).

Other Mechanisms
Another possible mechanism for the effects o f anabolic steroid usage is related to
the increased secretion o f other anabolic hormones. Anabolic steroids may also stimulate
growth hormone secretion in adults (Alèn & Rahkila, 1988). Hough (1990) noted that
during anabolic steroid administration, growth hormone secretion is between S and 60
times greater than baseline measurements.
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Alèn et al. (1984), Hâkkinen and Alen (1986), and Bardin et al. (1991) have
suggested that anabolic steroids may only be effective in large doses. Because relatively
low receptor affinities characterize most of the anabolic steroids, high doses o f these
drugs should be administered in order to obtain any anabolic effects greater than those
due to the natural training stimulus (Alèn et al., 1984; Hâkkinen & Alen, 1986). The
effects o f anabolic steroids may be uniform, but o f a small magnitude so that they are
statistically difficult to demonstrate (Bardin et al., 1991). However, even small effects
could be a benefit to a top athlete. As the caliber o f the athlete increases, the effects on
athletic performance become more difficult to assess (Wilson, 1988). The effects may
be related to the log of the dose, and benefits on performance may be observed at 10 or
more times the replacement dose for hypogonadal men (Bardin et al., 1991). Studies
showing the maximal effects of androgens in animals are only observed at
supraphysiological doses support this hypothesis (Bardin et al., 1991).
Bardin et al. (1991) have hypothesized that there is genetic polymorphism
among individuals. Only a small subset w ill show a large response to the administration
of anabolic steroids. Studies in inbred mice show that some strains have as much as a 20fold greater response to anabolic steroids than others (Bardin et al., 1991). Hough (1990)
has stated that individual differences in the responses to anabolic steroids are well known.

Steroid Alternatives
In 1990, the federal government passed the Anabolic Steroid Control Act (Yesalis
& Wright, 1993), listing anabolic steroids as Schedule III controlled substances. With the
passage o f this law, the Drug Enforcement Agency (DEA) controls the manufacture.
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importation, distribution and dispensing o f anabolic steroids (Yesalis & Wright, 1993).
Possession of anabolic steroids without a legitimate prescription is now a criminal
offense. When this law went into effect, some athletes and bodybuilders were unable to
find a source to supply them with anabolic steroids. Many athletes turned to dietary
supplements with hopes that their use would produce results similar to anabolic steroid
administration.

Dehydroepiandrosterone
While many different supplements have been marketed to athletes as steroid
alternatives, the most popular have been "testosterone precursors” , such as
dehydroepiandrosterone (DHEA) and androstenedione. Testosterone precursors are
administered with the belief that their use w ill increase endogenous testosterone
production in the body, and therefore, produce effects similar to those seen when
anabolic steroids are administered (McArdle et al., 1999). The use of testosterone
precursors has increased in popularity since 1996 when they were first sold as dietary
supplements in the USA (Brooks et al., 2000). DHEA was the first testosterone precursor
marketed to athletes. Brown et al. (1999c), Wallace et al. (1999), and Welle, Jozefowicz,
and Statt (1990) determined that supplementation with DHEA does not increase serum
testosterone or protein metabolism. Thus, DHEA was not found to be an effective
alternative to anabolic steroid usage. Recently, androstenedione was marketed as the
newest version o f testosterone precursor purported to increase serum testosterone
concentrations and act like anabolic steroids in the body.
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Androstenedione and Androstenediol
Androstenedione (Figure 2) is a steroid hormone produced endogenously in the
gonads and adrenal glands of all humans (Leder et al., 2000). The production of
androstenedione is approximately 3.4 mg per day in females and 1.4 mg per day in males
(Horton & Tait, 1966). Androstenedione is synthesized from dehydroepiandrosterone
and can be converted into testosterone via the enzyme 17 p-hydroxysteroid
dehydrogenase (Leder et al., 2000). Androstenedione serves as the immediate precursor
to testosterone in the endogenous production of testosterone (Wallace et al., 1999).
Androstenedione is characterized as a weak androgen in humans, with only minimal
amounts being converted into testosterone in males (Wallace et al., 1999). In males, a
greater amount is converted into estrogen hormones (Wallace et al., 1999). In females, as
much as 60% of their testosterone may come from the peripheral conversion o f
androstenedione to testosterone (Horton & Tait, 1966). Androstenedione also serves as
an immediate precursor to the hormone estrone (E l), which can then be converted into
the more metabolically active estrogen, estradiol (E2) (Longcope, Kato & Horton, 1969).
This conversion o f androgens to estrogens takes place to a greater extent in males when
compared to females (Longcope et al., 1969). While previous studies (Longcope et al.,
1969; Edman, C.D., Aiman, E.J., Porter, J.C., & MacDonald, P.C., 1978; Kley,
Deselaers, Peerenboom, & Kniskemper, 1980) have found that adipose tissue contains
the enzyme aromatase, which aromatizes androgens to estrogens, Matsumine, Hirato,
Yanaihara, Tamada, & Yoshida (1986) found that skeletal muscle in both males and
females can also convert androgens into estrogens. Edman et al. (1978) stated that the
skin and the brain can also aromatize androgens into estrogens. This peripheral
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aromatization o f androgens (including androstenedione) is the main source o f estrogens
in males, and represents a substantial amount o f the estrone produced in females
(Longcope et al., 1969). In males (Thomson, Wallace, & Cook, 1989) and females
(Diagnostic Products Corporation, 1999a), androstenedione exhibits a diurnal variation,
where it is highest in the morning; it also has cyclical variation during the female
menstrual cycle, where it is highest near the middle o f the cycle (Diagnostic Products
Corporation, 1999).

ANDR.OSTENEDIONE

Figure 2: Androstenedione Chemical Structure

Androstenediol (Figure 3) is another steroid hormone that can be converted to
testosterone in the body. According to Ballantyne et al. (2000), androstenediol can also
be synthesized from dehydroepiandrosterone and converted into testosterone via the
action o f the enzyme 3p-hydroxysteroid dehydrogenase (Earnest et al., 2000). The most
common pathway for the synthesis o f testosterone involves the degradation of
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pregnenolone to 17a-hydroxypregnenolone, to dehydroepiandrosterone, to
androstenediol, and finally to testosterone (Ballantyne et al., 2000). Testosterone can
also be synthesized by another pathway involving the conversion of pregnenolone to
progesterone and the subsequent formation of 17-hydroxypregnenolone and
androstenedione, which can be converted to estrone (then to estradiol) or testosterone
(Ballantyne et al., 1999).

OH

ANDROSTENEDIOL

Figure 3; Androstenediol Chemical Structure

Androstenedione and Androstenediol Studies
Early studies with androstenedione and other testosterone precursors (including
androstenediol) were completely unrelated to their possible use as ergogenic aids.
Instead, the early studies were conducted in an attempt to determine if weaker androgens
could be converted into more potent ones. In general, the results indicated that human
blood does contain the enzymes necessary to convert weaker androgens (like
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androstenedione) into stronger ones (like testosterone) (Mahesh & Greenblatt, 1962;
Horton & Tait, 1966; Blaquier, Forchielli, & Dorfman, 1967).
Mahesh and Greenblatt (1962) found that orally administered
dehydroepiandrosterone and androstenedione could be converted into testosterone in
females. Dehydroepiandrosterone ingestion resulted in a 3-4-fold increase in plasma
testosterone, while androstenedione ingestion caused a 4-7-fold increase in plasma
testosterone.
Horton and Tait (1966) found that in females, a significant amount o f testosterone
is derived from androstenedione (as high as 60% peripheral conversion of
androstenedione to testosterone). In males, plasma androstenedione conversion to
testosterone is less than 0.3%. A negligible amount of plasma testosterone comes from
androstenedione in males. One of the major findings of this study was that only 1.8% of
orally administered androstenedione and 5.9% o f intravenous androstenedione enters the
plasma as testosterone.
Blaquier et al. (1967) demonstrated that androgen transformation and
interconversions could take place in human blood. Small amounts of
dehydroepiandrosterone were converted to androstenedione and testosterone. Larger
amounts of androstenedione were converted to testosterone, but the androgen that was
most readily (highest percentage) converted into testosterone was androstenediol. The
researchers concluded that human blood can convert less active androgens into more
biologically active ones.
The first reported use o f androstenedione as an ergogenic aid came firom East
Germany, where athletes began administering it as early as 1981 (Franke & Berendonk,
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1997). The androstenedione was not taken orally; instead, it was administered via a nasal
spray (Franke & Berendonk, 1997).
Other than the original early studies performed on testosterone precursors, no data
was available to assess the possible ergogenic benefits o f their use. As a result, a number
o f studies have recently been performed to test whether these dietary supplements
increase serum concentrations o f testosterone and muscle size and strength (Ballantyne et
al., 1999; Brown et al., 1999a; Brown et al., 1999b; King et al., 1999a; King et al., 1999b;
Parsons et al., 1999; Quindry et al., 1999; Reifenrath et al., 1999; Wallace et al., 1999;
Earnest et al., 2000; Leder et al., 2000; Rasmussen et al., 2000). To date almost all
studies have investigated the orally administered versions of the testosterone precursor
dietary supplements, with androstenedione being the most often used.
The results o f the majority o f the studies indicate that orally administered
testosterone precursors do not increase serum testosterone concentrations or muscle size
and strength (Ballantyne et al., 1999; Brown et al., 1999a; Brown et al., 1999b; King et
al., 1999a; King et al., 1999b; Parsons et al., 1999; Quindry et al., 1999; Reifenrath et al.,
1999; Wallace et al., 1999; Rasmussen et al., 2000). Wallace et al. (1999) explained that
the bioavailability o f oral testosterone precursors is only approximately 5%, due to the
effects o f digestion, liver metabolism, and tissue enzyme activity. Horton and Tait
(1966) found that 89% o f orally administered androstenedione is converted to
testosterone glucuronide and excreted in the urine.
Wallace et al. (1999) conducted a study to compare the effects o f short-term
dehydroepiandrosterone (DHEA) versus androstenedione supplementation on body
composition, muscular strength, and hormonal levels in middle-aged male weightlifters.
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Participants were randomly divided into groups who received either 100 mg/day of a
placebo, androstenedione, or dehydroepiandrosterone. No significant changes were
observed in any measure o f muscular strength (bench press or leg press), body
composition (total body mass, lean body mass, or fat mass) or hormonal levels
(testosterone or androstenedione). These results indicated that supplementation with
either androstenedione or dehydroepiandrosterone did not increase lean body mass or
muscular strength levels compared to the placebo.
Quindry et al. (1999) administered either 200 mg/day o f a placebo,
androstenedione, or androstenediol to 50 middle-aged men in combination with heavy
resistance weight training, for a 12-week period. Both the androstenedione and
androstenediol groups demonstrated increases in serum androstenedione o f 183% and
62%, respectively. At one- and two- month periods, the androstenedione group
demonstrated a significant increase in total testosterone, which returned to normal by the
end o f the treatment period. No changes in serum testosterone levels were found in the
androstenediol group. Estrogen concentrations were significantly increased in the
androstenedione group at each measurement (1,2, and 3 months). The androstenediol
group only had significantly increased estrogens at the end o f the treatment period (3
months). The investigators concluded that the main effects o f oral androstenedione or
androstenediol administration in middle-aged men are significant increases in estrogenrelated hormones and a down-regulation in testosterone synthesis within one month of
continuous androstenedione use.
The acute (Parsons et al., 1999) and long-term (Brown et al., 1999b), (King et al.,
1999a), (Reifenrath et al., 1999) effects o f an anabolic supplement, AN6 (containing

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

55

androstenedione), have been investigated in college-aged males. Participants received
either a placebo, DHEA, or AN6. The results o f acute administration indicated that
serum androstenedione was increased following the intake o f DHEA and AN6. Neither
serum testosterone nor estradiol were increased following acute administration o f AN6
(Parsons et al., 1999). In the long-term studies, serum testosterone and estradiol
concentrations (King et al., 1999a), body composition and muscle strength (Reifenrath et
al., 1999), and glucose tolerance, insulin action and blood lipids (Brown et al., 1999b)
were examined in a group o f college-aged males undergoing 8 weeks o f resistance
training supplemented with either a placebo, DHEA, or AN6. Serum testosterone was
unaffected by any supplement. Serum estradiol and estrone levels were elevated with
AN6 supplementation. The investigators concluded that AN6 does not increase serum
testosterone, but increased androgen conversion to estrogens. AN6 also did not enhance
changes in muscle strength or body composition during strength training. The AN6
supplement was shown to reduce serum HDL cholesterol, increasing the risk for coronary
artery disease. In addition, insulin sensitivity was not increased with strength training
during AN6 supplementation.
Brown et al. (1999a) investigated the effects of placebo, androstenedione (300
mg/day), or androstenediol (300 mg/day), combined with herbal extracts, on serum sex
steroid levels in middle-aged men. Serum testosterone was unchanged in any group;
serum androstenedione and estradiol were significantly elevated in the androstenedione
and androstenediol groups. The researchers concluded that androstenedione and
androstenediol do not increase serum testosterone levels.
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King et al. (1999b) investigated the acute and long-term effects o f oral
androstenedione supplementation in combination with a weight training program. Thirty
healthy young men volunteered for the study. First, the short term effects of
androstenedione supplementation were investigated in ten participants in a crossover,
double-blind fashion. The participants received either 100 mg o f androstenedione or a
placebo. Blood samples were drawn every 30 minutes for six hours and analyzed for the
androstenedione and for free and total testosterone concentrations. The results indicated
that ingestion of androstenedione increased the serum androstenedione concentration up
to 325-350 %. However, serum concentrations o f free and total testosterone were
unaffected. The effects o f androstenedione during strength training were investigated in
the other 20 participants, who were randomly assigned into a group who received either
300 mg o f androstenedione (treatment group) or a placebo (control group) daily for 6 of
the 8 weeks o f the weight training program. The serum androstenedione concentration
was significantly elevated in the treatment group. Even though serum free testosterone
concentrations were significantly higher in the treatment group before and following the
treatment, the androstenedione supplementation did not significantly alter free
testosterone concentrations in either group. Total testosterone was also unaffected in
either group following treatment. Serum estradiol and estrone concentrations were
significantly elevated in the treatment group after supplementation and when compared to
the control group. Weight training caused a significant increase in muscle strength in
both groups, with no significant differences between the two groups. Mean crosssectional area o f the type II muscle fibers increased similarly in both groups. The
investigators concluded that supplementation with androstenedione, both long- and short
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term, did not significantly alter serum testosterone concentrations, muscle size, or muscle
strength in healthy young males. Serum estradiol and estrone concentrations were
significantly elevated following androstenedione supplementation, indicating
aromatization of androstenedione or o f testosterone, possibly derived from the exogenous
androstenedione supplementation.
Ballantyne et al. (1999) investigated the effects of androstenedione
supplementation in healthy young males during normal activity and while undergoing
weight training. First, participants ingested 200 mg o f androstenedione daily for 2 days;
blood samples were drawn every three hours for twelve hours on the second day and
twenty-four hours after ingestion of the last p ill on the third day o f the experiment. At
least two weeks later, the same subjects, in a crossover design, were administered either
androstenedione or a placebo at a dosage o f200 mg per day for two days. Blood samples
were drawn just before, immediately after, and 90 minutes after a weight training
workout. The results demonstrated that androstenedione supplementation elevated serum
androstenedione levels 2-3-fold. There were no significant differences in testosterone
levels at any time o f the day during the supplementation periods. While estradiol
concentrations were higher during supplementation, the differences were not statistically
significant. Following exercise, free and total testosterone levels were elevated during
both conditions, with no significant differences as a result o f androstenedione
supplementation. Serum estradiol concentrations were also elevated following exercise,
and remained significantly elevated for at least 90 minutes after exercise with
androstenedione supplementation. During both conditions, serum testosterone was well
within the normal range and displayed a normal circadian rhythm. The researchers
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concluded that androstenedione supplementation had no effect on plasma testosterone
during a twenty-four hour period. The researchers also concluded that exercise interacted
with androstenedione supplementation to exaggerate the conversion o f androstenedione
to estradiol. According to this study, androstenedione supplementation appears to be of
no benefit to the male athlete.
Rasmussen et al. (2000) investigated the effects o f five days o f oral
androstenedione supplementation (100 mg/day) on muscle protein synthesis and serum
hormone levels. The results indicated that plasma androstenedione concentrations
increased three-fold, causing a significant increase in serum estradiol concentrations.
Plasma testosterone levels did not change during the investigation. An increase in muscle
protein breakdown was noticed during androstenedione supplementation. Muscle protein
synthesis was also slightly elevated during the supplementation, but the change was not
different from the control condition, nor was it as large as the increased muscle protein
breakdown. In other words, the net protein balance was negative during androstenedione
supplementation, indicating protein catabolism. This trend towards increased protein
breakdown was theorized to have been a consequence o f the increased estradiol levels.
The authors concluded that oral androstenedione supplementation did not stimulate
muscle protein anabolism or increase serum testosterone levels. Instead, it was theorized
that oral androstenedione was aromatized to estradiol and probably reduced and
conjugated for excretion by the liver. Previous studies have shown that 89% o f orally
administered androstenedione was converted to testosterone glucuronide and excreted in
the urine (Horton & Tait, 1966). Androstenedione was shown to have no direct anabolic
effects on muscle.
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Only two published studies indicated that testosterone precursor dietary
supplements do increase serum testosterone concentrations, and therefore might contain
ergogenic effects (Earnest et al., 2000; Leder et al., 2000).
Earnest et al. (2000) set out to determine if androgenic hormone precursors for
testosterone could be transformed into testosterone. Eight male participants were treated
in a crossover fashion with either 200 mg o f androstenedione, androstenediol, or a
placebo. Blood sample were drawn every 30 minutes for 90 minutes. Analysis o f the
data revealed that the mean area under the curve (AUC) for serum androstenedione was
greater during androstenedione administration than during androstenediol or placebo
administration. During androstenedione administration, a significant increase in free and
total testosterone was demonstrated when compared to the placebo group, but not the
androstenediol group. The investigators concluded that androstenedione, and possibly
androstenediol, when taken orally, can increase testosterone concentrations in healthy
young men.
Leder et al. (2000) investigated the effects o f oral androstenedione administration
on serum androstenedione, estradiol, estrone, and testosterone levels in healthy young
men. Participants were randomly divided into groups that received either 100 mg/day or
300 mg/day o f androstenedione, or placebo (0 mg/day) for seven days. The results
indicated that the mean changes in AUC for serum testosterone in the groups receiving 0,
100, and 300 mg/day o f androstenedione were -2%, -4%, and 34%, respectively. The
change in the 300 mg/day group was significant compared to the placebo and 100 mg/day
groups. In the 100 mg/day group, the mean AUC for androstenedione, estrone, and
estradiol increased 72%, 74%, and 42%» respectively. In the 300 mg/day group, the
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mean AUC for androstenedione, estrone, and estradiol increased 697%, 196%, and 128%,
respectively. Mean daily baseline serum testosterone and estrone concentrations did not
change, while mean daily serum androstenedione and estradiol increased significantly
over the seven day period in the 300 mg/day group. In the 100 mg/day group, no subjects
had serum testosterone concentrations that exceeded the upper lim it o f normal, but 4 of
14 subjects in the 300 mg/day group had levels that exceeded the upper lim it o f normal.
Twelve o f IS and 10 o f 14 participants in the 100 mg/day and 300 mg/day groups,
respectively, had estradiol levels above the upper lim it of normal for males. The
investigators concluded that higher doses of orally administered androstenedione can
increase serum testosterone and estrogen levels.
Even though Blaquier et al. (1967) found that androstenediol is more readily
converted into testosterone than any other androgen precursor, few studies (Brown et al.,
1999a; Quindry et al., 1999; Earnest et al., 2000) have investigated the possible ergogenic
effects o f this substance. Two o f the studies. Brown et al. (1999a) and Quindry et al.
(1999), concluded that androstenediol does not increase serum testosterone
concentrations, and therefore is not effective as an ergogenic aid. Earnest et al. (2000)
concluded that androstenediol possibly has ergogenic effects.
Only one study published to date has investigated an alternate delivery method
(transdermal) o f a testosterone precursor, androstenedione (Stoppe & Krause, 1986).
Stoppe and Krause (1986) administered percutaneous (transdermal) testosterone,
androstenedione (1.25 mg/m^body surface area), and estradiol to the skin o f healthy
young men to investigate the effects on serum steroid hormone levels. Testosterone and
estradiol administration led to short peaks in their respective serum concentrations.
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Androstenedione did not alter the serum levels of any o f the hormones measured. It was
concluded that precursor steroids, including androstenedione, are rapidly metabolized to
other compounds before they could reach the blood in any sizable amount.
While most studies have investigated whether androgen precursor supplements
can raise serum testosterone levels, one study looked at the urinary metabolites of
androgen precursor supplementation, and whether ingestion o f these products could lead
to a positive drug test for anabolic steroids. Uralets and Gillette (1999) investigated the
excretion products o f the orally administered androgen precursors androstenedione,
androstenediol, and norandrostenedione. After oral administration of androstenedione,
all participants had significantly higher concentrations o f androsterone and
etiocholanolone in their urine. Androsterone and etiocholanolone are two o f the major
urinary metabolites o f testosterone (Schânzer, 1996). Urinary testosterone and
epitestosterone concentrations also rose briefly, with testosterone rising faster than
epitestosterone. This rapid rise in testosterone, coupled with the fact that most men
respond to androstenedione administration with a greater rise in urinary testosterone (T)
relative to epitestosterone (E), could cause the T/E ratio to rise over 6, which would result
in a positive drug test for the use o f anabolic steroids. The urinary metabolites
disappeared in less than 24 hours. The researchers explained that it is uncertain whether
the ingestion o f androstenedione would cause an increase in serum testosterone, because
androstenedione, like other anabolic steroids has a high rate o f metabolic inactivation
when administered orally. Androstenediol administration caused an increase in urinary
testosterone ten times greater than that o f androstenedione. Epitestosterone also rose to
levels greater than were seen during androstenedione administration; thus the T/E ratio
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was not as high as in androstenedione administration. The urinary metabolites
disappeared after 20 hours. The main excretion products of norandrostenedione are
norandrosterone and noretiocholanolone, the same metabolites as the anabolic steroid
nandrolone (nortestosterone), because norandrostenedione is rapidly converted to
nortestosterone. The concentrations o f the major metabolites in the first urine samples
were as high as 100,000 ng/ml, higher than seen with the injectable (parenteral) anabolic
steroid nandrolone. Other than the unusually high first urine output, the urinary
metabolites of norandrostenedione are identical to those of nandrolone. Norandrosterone
and noretiocholanolone are detectable in a urine sample up to 10 days after a single SO
mg dose. This study indicated that supplementation with androstenedione and
norandrostenedione could cause the user to fail a drug test for anabolic steroids.
When all o f the available data on androstenedione administration in males is
analyzed, most studies have concluded that orally administered androstenedione is not
converted to testosterone; it is instead aromatized into estrone, which can then be
converted into estradiol. Therefore, androstenedione and the other popular testosterone
precursors have no performance enhancing actions in males.
To date, no studies have assessed the possible ergogenic benefits o f
androstenedione supplementation in females. Mahesh & Greenblatt (1962) found that
ingestion o f androstenedione did increase testosterone levels for a short time. Horton &
Tait (1966) found that as much as 60% o f the testosterone in females may come from the
peripheral conversion o f androstenedione to testosterone. It is theorized that, because
females have a much lower circulating level o f testosterone when compared to males.
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increasing the level o f testosterone could lead to greater increases in muscle mass and
strength (MacDougall, 1983; George, 1988; Lombardo, 1993).
In summary, while exogenous testosterone administration has been shown to
increase serum testosterone levels, thus improving athletic performance by increasing
muscle size and strength, it has been concluded that the administration o f testosterone
precursors, including androstenedione and androstenediol, does not increase serum
testosterone levels in males. A ll but one o f the studies have looked at orally administered
androstenedione. To date, no studies have investigated the possible ergogenic effects of
testosterone precursor supplementation in females, or the effects o f the administration of
a transdermal testosterone precursor containing androstenedione and androstenediol.
Therefore, the purpose o f my study is to examine the acute effects o f transdermal
androstenedione and androstenediol administration (the dietary supplement
AndrosteDERM®) on the serum steroid hormone levels o f androstenedione and free and
total testosterone in females.
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CHAPTERS

METHODOLOGY
Subjects
Seven healthy college-aged females volunteered to participate in this study. The
participants were selected on the basis o f being in general good health, not being
pregnant, and no previous history o f anabolic steroid, testosterone, or testosterone
precursor supplementation. The average age (and standard deviation) of the participants
was: 23.43 ± 4.31 years. Participants signed an informed consent (Appendix I) prior to
participation. The UNLV Institutional Review Board approved the use o f human
subjects for this study (Appendix I).

AndrosteDERM®
AndrosteDERM® is a transdermal testosterone precursor cream produced by
Medlean (Duxbury, MA). It contains the testosterone precursors androstenedione and
androstenediol, and is sold without a prescription at a number o f health food retailers as a
dietary supplement. The recommended daily dosage o f 2 ml is supposed to contain 130
mgs o f a mixture o f androstenedione and androstenediol. The cream is to be applied once
daily to any number o f locations including the inner upper arm, the inner thigh, and the
back.
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In order to assure purity, a 10 ml sample of AndrosteDERM® was sent to
Integrated Biomolecule Corporation (Tucson, AZ) for a HPLC purity assay. The results
o f the assay (Appendix II) indicated that I ml o f AndrosteDERM® contained 21.8 ± 0.26
mg of androstenedione and 44.6 ± 0.37 mg of androstenediol. These results are in
agreement with the manufacturers claim that 2 ml o f AndrosteDERM® contained, in
total, 130 mg o f a mixture o f androstenedione and androstenediol.

Test Protocol
A ll testing was conducted in the morning, beginning between 8am and 12pm, to
account for the normal diurnal variation in androstenedione levels (Diagnostic Products
Corporation, 1999). Subjects were advised to go about their normal daily schedules on
the day o f testing; the subjects need not be fasted, and no other special preparations are
necessary for proper analysis (Diagnostic Products Corporation, 1999).
Using aseptic technique, a registered nurse drew an approximately 6 ml baseline
sample o f blood from an antecubital vein. One ml o f the AndrosteDERM® cream was
applied to the inner surface o f the left upper arm. Every 45 minutes for the next six hours
following the initial application o f the AndrosteDERM®, another approximately 6 ml
sample o f blood was drawn. A total of nine samples o f blood, totaling approximately 54
mis, were drawn.

Blood Analysis
The collected blood samples were centrifuged at 700 xg for 12 minutes the same
day; the plasma was removed and frozen at - 80 °C until analysis. Serum
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androstenedione and free and total testosterone concentrations were analyzed using
radioimmunoassay (Diagnostic Products Inc., Los Angeles, CA) by an independent
laboratory. An independent laboratory was chosen do perform the radioimmunoassay
procedures because the University of Nevada, Las Vegas lacks the equipment and
experienced personal.

Design
The study was a 1 (Subject) X 9 (Time) within-subjects design. The factor time
had nine levels; 0 minutes (baseline), 45 minutes, 90 minutes, 135 minutes, 180 minutes,
225 minutes, 270 minutes, 315 minutes, and 360 minutes post treatment. The dependent
variables o f interest were serum androstenedione, free testosterone, and total testosterone
concentration.
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CHAPTER 4

RESULTS AND DISCUSSION
Serum Androstenedione Concentration
When the serum androstenedione values calculated from the radioimmunoassay
procedure were assessed, a number of the values were beyond the expected physiological
level for females (Diagnostic Products Corporation, 1999a) (Table I). A ll data from
Table 1 appears in Figure 4. However, values such as 44.47 ng/ml, 17.03 ng/ml and
57.70 ng/ml are beyond the expected range for females (males as well) (Diagnostic
Products Corporation, 1999a). Subjects who had at least one value that was beyond the
expected range of 0.4 to 2.7 ng/ml (Diagnostic Products Corporation, 1999a) were
excluded, leaving one subject. Subject I (Table 2). This made statistical analysis
impractical.

Table I: Androstenedione Raw Data For A ll Subiects tin ng/ml)

Subject 1
Subject 2
S u t^ 3
Subject 4
Subject 5
Subject 6
Subject 7

Omin 4Smin 90min 135 min 180 min 225 min 270
1.68
1.66
1.92
2.03
1.85
1.61
2.44
3.33
28.83
2.73
2.60
2.40
44.47
7.82
4.52
7.76
8.23
9.28
4.77
4.05
4.00
4.63
7.16
8.85
19.16
6.98
6.11
5.75
5.33
5.91
4.41
23.39
3.56
3.02
3.97
3.60
7.60
2.80
5.62
2.61
2.40
2.88

min 315 min 360 min
1.26
1.26
1.39
2.74
2.55
2.19
8.84
7.73
9.49
7.52
17.03
3.99
6.14
8.25
6.72
4.77
4.14
3.75
4.62 57.70
3.23
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Figure 4; Serum Androstenedione Versus Time Plot For A ll Subjects

Table 2: Androstenedione Values fin ng/ml) (Exclusion of Unexpected Values)*

Subject 1

Omin 4 5 min 9 0 min 135min 180min 2 2 5 min2 7 0 min 3 1 5 min 36 0 min
1.68
1.66
1.92
2.03
1.85
1.61
1.26
1.26
1.39

* Values that were beyond the expected values range (Diagnostic Products Corporation,
1999a) were excluded which resulted in 6 of the 7 subjects being excluded

The data from Subject I (Table 2) appears in Figure S. The serum
androstenedione concentration for Subject I appeared to rise slightly from 45 minutes
post application to 225 minutes post application. It then fell below baseline for the rest of
the testing period. This could be due to absorption of the AndrosteDERM® or the
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normal diurnal androstenedione variation for females (Diagnostic Products Corporation,
1999a).

Subject 1 Androstenedione
s- 2.5

0.5

0

45
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315

360

Time (min)

Figure 5: Serum Androstenedione Versus Time Plot For Subject 1

Serum Free Testosterone Concentration
When the serum free testosterone values calculated from the radioimmunoassay
procedure were assessed, a number of the values were beyond the expected physiological
level for females (Diagnostic Products Corporation, 1999b) (Table 3). A ll data from
Table 3 appears in Figure 6. However, values such as 202.88 pg/ml, 63.82 pg/ml and
69.88 pg/ml are beyond the expected range for females (Diagnostic Products
Corporation, 1999b). Subjects who had at least one value that was beyond the expected
range of 0.06 to 2.57 pg/ml (Diagnostic Products Corporation, 1999b) were excluded,
leaving one subject. Subject 1 (Table 4). This made statistical analysis impractical.
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Table 3: Free Testosterone Raw Data For A ll Subiects (in pg/mO

Subject 1
Subject 2
Subject 3
Subject 4
Subject 5
Subject 6
Subject 7

Omin 4 5 min 9 0 min 135min 180min 2 2 5 m in2 7 0 min 3 1 5 m in3 6 0 min
0.94
0.87
1.01
1.28
1.08
1.30
1.77
2.15
1.95
1.49
1.33
1.47
5.85
1.43
1.89
1.92
3.34
1.86
9.24
24.89
43.60
36.59 39.13
26.16 34.49
45.13
202.88
17.33
63.82
20.64
6.12
14.96 26.64
6.35
12.35
7.42
5.06
17.56 13.62
6.69
7.58
22.09
17.63
13.75
6.82
5.87
69.88
4.28
3.19
3.88
6.53
3.93
6.23
6.24
2.12
2.70
1.79
3.38
8.10
8.23 89.92
9.88
9.06
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Figure 6: Serum Free Testosterone Versus Time Plot For A ll Subjects
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Table 4: Free Testosterone Values fin pg/mll (Exclusion of Unexpected Values)*

Subject 1

Omin 4 5 min 9 0 min 1 35min 180min 2 2 5 min 2 7 0 min 3 1 5 min 3 6 0 min
2.15
0.94
1.01
0.87
1.28
1.08
1.30
1.95
1.77

* Values that were beyond the expected values range (Diagnostic Products Corporation,
1999b) were excluded, which resulted in 6 of the 7 subjects being excluded

The data from Subject 1 (Table 4) appears in Figure 7. The serum free
testosterone concentration for Subject 1declined sharply from application to 45 minutes
post application. It then began to rise, reaching near baseline concentration at 315
minutes post application.

Subject 1 Free Testosterone
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Figure 7: Serum Free Testosterone Versus Time Plot For Subject 1
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Serum Total Testosterone Concentration
When the serum total testosterone values calculated from the radioimmunoassay
procedure were assessed, a number of the values were beyond the expected physiological
level for females (Diagnostic Products Corporation, 1999c) (Table 5). A ll data from
Table 5 appears in Figure 8. However, values such as 3290.03 ng/dl, 225.42 ng/dl and
130.06 ng/dl are beyond the expected range for females (Diagnostic Products
Corporation, 1999c). Subjects who had at least one value that was beyond the expected
range of 0 to 81 ng/dl (Diagnostic Products Corporation, 1999c) were excluded, leaving
two subjects. Subjects 1 and 2 (Table 6). This made statistical analysis impractical.

Table 5: Total Testosterone Raw Data For A ll Subjects (in ne/dl)

Subject 1
Subject 2
Subject 3
Subject 4
Subject 5
Subject 6
Subject 7

Omin
4 5 min 9 0 min 135min 180min 2 2 5 m in2 7 0 min 3 1 5 min3 6 0 min
24.11 10.65
19.88
16.81
20.57 16.24
14.41 32.50
20.12
29.88 75.48 30.78
36.86
33.59 38.27
45.26 56.17
57.79
3290.03 49.16 93.68
89.18 240.25 84.63
195.96 240.36 256.29
46.90 52.06 132.91
79.05 225.42 50.40
104.98 53.25
84.51
72.80 651.05 64.27
41.07
50.79 52.49
96.00 93.05
65.97
62.77 333.09 47.37
53.59
69.78 97.31
93.39 130.06 151.39
103.71 32.26 31.09
37.72
54.45 86.72
97.35 868.62
51.29
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Figure 8: Serum Total Testosterone Versus Time Plot For A ll Subjects

Table 6; Total Testosterone Values (in ng/dl) (Exclusion of Unexpected Values)*

Subject 1
Subject 2

Omin
4 5 min 9 0 min 135min 180min 2 2 5 min2 7 0 min 3 1 5 m in3 6 0 min
24.11 10.65 19.88
16.81
20.57 16.24
14.41 32.50
20.12
29.88 75.48 30.78
36.86
33.59 38.27
45.26 56.17
57.79

* Values that were beyond the expected values range (Diagnostic Products Corporation,
1999c) were excluded which resulted in 5 of the 7 subjects being excluded

The data from Subjects 1 and 2 (Table 6) appears in Figure 9. The serum total
testosterone concentration for Subject 1 declined sharply from baseline to 45 minutes
post application. The general trend for the rest of the testing period was to rise, reaching
a peak level at 315 minutes post application. For Subject 2, the total testosterone
concentration rose sharply from baseline to 45 minutes post application. It then declined
to approximately baseline levels at 90 minutes post application. From 90 minutes post
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application, the general trend for Subject 2 was a steady increase in total testosterone,
reaching a peak concentration at 360 minutes post application. Whether serum total
testosterone levels continued to rise after that point is unknown. This increase in total
testosterone could be caused by the peripheral conversion of androstenedione or
androstenediol supplied via AndrosteDERM®.

Subject 1 and 2 Total Testosterone
80.00
60.00

% % 40.00
20.00

0.00
Time (min)
Subject 1 -e-S u b ject 2

Figure 9: Serum Total Testosterone Versus Time Plot for Subjects I and 2

While serum androstenedione, free and total testosterone levels were analyzed
using radioimmunoassay, much of the data received (including baseline levels) was
beyond the physiological levels possible for females, indicating a methodological error.
Therefore, the data for most of the subjects had to be eliminated from statistical analysis.
While the general trend did not indicate a rise in serum androstenedione, free or total
testosterone following application, too few subjects remained following elimination to
run the appropriate statistical analysis.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

CHAPTERS

SUMMARY AND RECOMMENDATIONS
Summary
Testosterone is an anabolic hormone; it promotes the building o f new tissue, such
as skeletal muscle, by increasing protein synthesis (anabolic action) and decreasing
protein breakdown (anticatabolic action) (Blue & Lombardo, 1999). The serum
concentration of testosterone in males is ten times that o f females (Gard, 1998), which
Wynn (1975) states is responsible for the greater amount o f muscle mass seen in males.
Anabolic steroids are synthetic versions o f the hormone testosterone. Because
anabolic steroids have powerful tissue building effects, it is believed that their use w ill
cause the accretion o f skeletal muscle mass and strength, although, the exact mechanism
at work remains unknown.
With the scheduling of anabolic steroids as controlled substances in 1990 (Yesalis
& Wright, 1993), the possession o f anabolic steroids without a legitimate medical
prescription became a criminal ofifense. Many athletes and bodybuilders turned to legal
dietary supplements in hopes that their use would produce effects similar to those o f
anabolic steroids. Some o f the most popular dietary supplements purported to have
“muscle building” effects similar to anabolic steroids are testosterone precursors (or
prohormones), with androstenedione and androstenediol being two o f the most popular.
In the human body, both androstenedione and androstenediol serve as immediate
75
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precursors to the hormone testosterone (Wallace et al., 1999; Earnest et al., 2000).
Androstenedione can be converted to testosterone via the hormone 17 P-hydroxysteroid
dehydrogenase (Leder et al., 2000). Androstenediol can be converted into testosterone
via the enzyme 3p-hydroxysteroid dehydrogenase (Earnest et al., 2000). Thus, it is
theorized that if these testosterone precursor supplements are administered, they w ill be
converted into testosterone, increasing the serum testosterone concentration. It is
believed that by increasing the endogenous production o f testosterone in the body, results
similar to those seen during anabolic steroid administration (increased muscle mass and
strength) w ill be recognized.
Recently, a number o f studies (Ballantyne et al., 1999; Brown et al., 1999a;
Brown et al., 1999b; King et al., 1999a; King et al., 1999b; Parsons et al., 1999; Quindry
et al., 1999; Reifenrath et al., 1999; Wallace et al., 1999; Earnest et al., 2000; Leder et al.,
2000; Rasmussen et al., 2000) bave been conducted on males to determine if the use o f
oral testosterone precursors, including androstenedione and androstenediol, w ill increase
serum testosterone levels, and produce anabolic effect seen while using anabolic steroids.
The results o f the majority o f the studies indicate that orally administered testosterone
precursors do not increase serum testosterone concentrations or muscle size and strength
(Ballantyne et al., 1999; Brown et al., 1999a; Brown et al., 1999b; King et al., 1999a;
King et al., 1999b; Parsons et al., 1999; Quindry et al., 1999; Reifenrath et al., 1999;
Wallace et al., 1999; Rasmussen et al., 2000). Only two published studies indicated that
supplementation with testosterone precursor dietary supplements does increase serum
testosterone concentrations, and therefore, may have ergogenic value (Earnest et al.,
2000; Leder et al., 2000).
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It has been detennined that the bioavailability o f oral testosterone precursors is
only approximately 5%, due to the effects o f digestion, liver metabolism, and tissue
enzyme activity (Wallace et al., 1999). Thus, alternate methods for testosterone
precursor delivery have been developed in an attempt to increase their bioavailability.
Transdermal and sublingual versions o f androstenedione and androstenediol have been
marketed with claims stating better results than those seen with oral testosterone
precursors.
Only one study published to date has investigated an alternate delivery method
(transdermal) o f a testosterone precursor, androstenedione (Stoppe & Krause, 1986).
Stoppe and Krause (1986) administered percutaneous (transdermal) testosterone,
androstenedione (1.25 mg/m^body surface area), and estradiol to healthy young men in
order to investigate the effects on serum steroid hormone levels. Testosterone and
estradiol administration led to short peaks in their respective serum concentrations.
Androstenedione did not alter the serum levels of any o f the hormones measured,
including androstenedione and testosterone. It was concluded that precursor steroids,
including androstenedione, are rapidly metabolized to other compounds before they can
reach the blood in any sizable amount. In the case o f androstenedione, it would be
metabolized in the liver to such products as androsterone, etiocholanone, 5a- and 5pandrostandiols (Uralets & Gillette, 1999), and testosterone glucuronide (Horton & Tait,
1966) to be excreted in the urine.
To date, no studies have ever been conducted on females to determine whether
testosterone precursor administration may behold ergogenic benefits. I f testosterone
precursor dietary supplements do increase serum testosterone levels, and thus hold
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ergogenic benefits, females should exhibit a greater response to their administration
because of much lower serum testosterone concentrations and the fact that as much as
60% of testosterone in females comes for the peripheral conversion o f androstenedione
(Horton & Tait, 1966).
Mahesh and Greenblatt (1962) found that orally administered
dehydroepiandrosterone and androstenedione could be converted into testosterone in
females. Ingestion o f 100 mgs o f androstenedione caused a 4-7-fold increase in plasma
testosterone. The researchers concluded that androstenedione could be converted into
testosterone in the human body. The present study was designed to determine whether
the acute administration of a transdermal testosterone precursor supplement in females
(AndrosteDERM®) would elevate serum androstenedione and free and total testosterone
levels above baseline over the six hour testing period.
In the present study, the data obtained as a result of the radioimmunoassays may
not be correct, making the results obtained questionable. While all blood collection was
performed properly, an error appeared to have occurred somewhere between sampling
and the final results. Some o f the subsequent data obtained was not physiologically
possible for men or women. Proper interpretation o f the data is unwarranted without
retesting all o f the blood samples. Conclusions and generalizations cannot be made at
this time.

Recommendations
Based on the current study, the following recommendations are offered for future
research:
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1.

Conduct the study with a larger number of subjects. For monetary reasons,
this study could only use seven subjects, and because of apparent errors that
occurred somewhere after the blood collection, a number of the subjects had
to be eliminated from statistical analysis because of unexpected values. This
left either one or two subjects depending on the dependant variable. An
increase in the number of subjects could potentially offset a similar problem in
a similar study.

2.

Conduct each sample in duplicate (or triplicate) during the radioimmunoassay
procedure. Errors occurred somewhere after collection of the blood samples.
If the errors were in the radioimmunoassay, performing duplicate (or
triplicate) analyses on each sample could potentially document that error.

3.

Increase the testing period beyond six hours. More blood sample could have
been collected 12, and possibly 24, hours post application in order to test for a
sustained increase in androstenedione, free or total testosterone.

4.

Either in males or females, a shidy with a longer duration could be conducted.
Instead of the acute effects of a one time application of AndrosteDERM®, the
effects of application of AndrosteDERM® for one week or longer could
determine whether continued usage w ill elevate androstenedione, free or total
testosterone levels, and if the increase is sustained for a period of time.

5.

Analyze other metabolites or hormones. A urine analysis could detect
metabolites that may cause a failed drug test for anabolic steroids. Analyzing
serum estrogen levels (estrone and estradiol) could determine if the
androstenedione is being converted into testosterone or estrogen hormones.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

APPENDIX I
IRC APPROVAL/INFORMED CONSENT

80

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

81

U N iy
DATE:

March 28,2001

TO:

FROM:

Mark Rasmussen
Kinesiology
M/S 3034

^

f
RE:

Dr. Carl Reiber
UNLV Biomedical Sciences Institutional Review Board
Status of Human Subject Protocol Entitled:
“The Acute Effects of AndrosteDERM Administration on Serum Steroid Levels
and Grip Strength”
OPRS# S04s0800-062

This memorandum is official notification that the UNLV Biomedical Sciences Institutional
Review Board approved the protocol for the project listed above and work on the project may
proceed. This approval is effective March 27,2001 and will continue for a period of one year.
Should the use of human subjects described in this protocol continue beyond a year from the
approval date, it will be necessary to request an extension.
If you have any questions or require any assistance, please contact the Office for the Protection of
Research Subjects at 895-2794.

cc: OPRS File

Office for the Protection of Research Subjects
4505 Maryland Parkway • Box 451046 • Las Vegas. Nevada 89154-1046
(7021895-2794 • FAX (702) 895-4242
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University of Nevada Las Vegas
Informed Consent Statement
THE ACUTE EFFECTS OF TRANSDERMAL TESTOSTERONE
PRECURSOR ADMINISTRATION ON SERUM STEROID
HORMONE LEVELS IN FEMALES

Information
You are invited to participate in a research study investigating the acute effects of
a transdermal testosterone precursor supplement, AndrosteDERM®, on the serum
steroid hormone levels o f androstenedione and free and total testosterone.
Procedures
You w ill be asked to report to the Sports Injury Research Center for one six-hour
testing session.
As listed on the packaging, AndrosteDERM® is an all-natural, non-prescription,
nutritional product (this product is labeled as a dietary supplement by the FDA,
not a food or a drug) that can be purchased at health food stores. It is a
transdermal (absorbed through the skin) version of the testosterone precursors
androstenedione and androstenediol, used for performance enhancement in sports
requiring power.
Dietary supplements are regulated under a different set o f regulations than those
covering foods and drugs (over-the-counter and prescription). Under the Dietary
Supplement Health and Education Act o f 1994 (DSHEA), the manufacturer of the
dietary supplement is responsible for ensuring that it is safe before it is marketed.
The FDA is then responsible for taking action against any unsafe dietary
supplement after it reaches the market, not before. In most cases, the
manufacturers o f dietary supplements do not need to register with the FDA or get
FDA approval before producing or selling their products.
The procedures of the study w ill be explained to you upon your arrival to the
Sports Injury Research Center. At this time, you w ill be asked to sign the
informed consent and participation in the study w ill begin. Using aseptic
technique, a registered nurse w ill draw a baseline blood sample (approximately 6
ml) from an antecubital vein (front o f the elbow). One (I) ml (21.8 mg o f
androstenedione and 44.6 mg o f androstenediol, a total o f 66.4 mg) of
AndrosteDERM® w ill be applied to the inner surface o f your left upper arm.
Blood samples o f 6-ml each w ill be drawn every 45 minutes for six hours from
the initial application o f AndrosteDERM®. The total amount o f blood drawn w ill
be approximately 54 mis.
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PRECURSOR ADMINISTRATION ON SERUM STEROID
HORMONE LEVELS IN FEMALES
Benefits of Participation
1. Satisfaction from participating in a research project and contributing to the
body o f human performance literature.
2. An increased understanding o f the acute effects o f testosterone precursor
supplementation on serum steroid hormone levels.
Risks
In this experiment, the risk to the participant is minimal. A registered nurse w ill
perform all o f the blood draws using aseptic technique. There is always a risk of
infection when a blood sample is drawn. The risk is minimized with the use of
disinfectants, gloves, aseptic technique, and sterile equipment. There is the risk of
bruising associated with any venipuncture. Bruising usually resolves in 7-10
days. This risk is minimized by using correct technique for blood drawing.
Sterile, one time use, disposable needles w ill be used. Universal blood and body
fluid precautions w ill be carried out at all times. Used needles w ill be disposed
immediately after use in a sharps container. The risk o f skin
redness or irritation following the application o f the topical cream is also possible.
The possible effects are mitigated with the one-time application o f a low dosage
o f AndrosteDERM®.
The researcher and a registered nurse w ill be monitoring you during the study. If
you feel any discomfort during the study, notify the researcher or the registered
nurse and the study w ill be stopped immediately. If any other problems should
arise, the researcher w ill address the situation.
There are no known risks associated with the acute administration o f a
testosterone precursor. Most studies conducted on testosterone precursors have
been performed on males, with no side effects being reported with their acute
(one-time) use. With chronic use (eight weeks), a lowering o f HDL cholesterol
was reported, although, the serum concentration did not reach a level that is
considered a risk factor for cardiovascular disease (King et al., 1999). No negative
side effects were reported in males who received either 100 or 300 mg of
androstenedione daily for seven days (short-term); the authors indicated that long
term use could be hazardous, particularly in women and children (Leder et al.,
2000).

Some potential side effects associated with the chronic use o f testosterone
precursors in males include elevated estrogen levels, which may cause
gynecomastia or other feminizing effects, and may increase the risk for
cardiovascular disease, and prostate and pancreatic cancer (King et al., 1999). In
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women, the chronic use o f testosterone precursors could elevate serum
testosterone levels, possibly causing hirsutism or virilization (Leder et al., 2000).
In the only known study on testosterone precursor administration in females, the
female participants ingested lOOmg of androstenedione (Mahesh and Greenblatt,
1962). Peak testosterone levels were noticed 60 minutes after administration and
had begun declining 90 minutes following administration (Mahesh and
Greenblatt, 1962). No side effects were reported with the one-time administration
o f the androstenedione, or the transient rise in testosterone (Mahesh and
Greenblatt, 1962). In the only known study ever to investigate the transdermal
administration o f a testosterone precursor, when the androstenedione was
administered to the male participants, no rise in serum androstenedione,
testosterone, or estradiol was reported (Stoppe and Krause, 1986).
The potential for side effects associated with the use o f testosterone precursors in
females is mitigated by the one-time (acute, not chronic) administration of a low
dose (66.4 mg) o f the testosterone precursor.
The effects o f an acute (one-time) dose o f AndrosteDERM® on the menstrual
cycle are unknown. Because serum testosterone levels may be elevated with the
application o f AndrosteDERM®, the date when menses occurs may be effected; it
may be either earlier or later than expected. Again, the effects on the menstrual
cycle are unknown.

Confct
If you have any questions at any time about the study, or if you experience
adverse effects as a result of participation in this study, you may contact the
researchers; Mark Rasmussen at 895-2780 or Dr. John Young at 895-4626. For
questions about your rights
as a research participant, you may contact the UNLV Office for the Protection of
Research Subjects at 895-2794.
Participation
Your participation in this study is voluntary. You may refuse to participate in this
study or in any part o f this study. At any time you may withdraw without
prejudice to your relations with UNLV or the director o f this study. I f you
withdraw, you should understand that your data would be destroyed. You may ask
any questions about this study prior to its beginning or at any time during the
investigation.
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PRECURSOR ADMINISTRATION ON SERUM STEROID
HORMONE LEVELS IN FEMALES
ConfidentuUitv
No reference w ill be made in written or oral materials that could link you to this
study A ll data w ill be placed in a locked cabinet in the Sports Injury Research
Center at UNLV.

Copwnt
I have read and understand the above information. My questions have been
answered by the director o f the study. I agree to participate in this study.

Subject s Signature

Date

Researcher’s Signature

Date
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QUESTIONNAIRE
Participant Initials (first, middle, last)
Participant Number (leave blank)
SECTION 1; General Information
1. Name:
2. Age:
SECTION 2: Medical History
1. Because androgen levels could change during this study, it would be inappropriate to
include any women who are, or might be pregnant. Are you, or is there any chance
that you might be pregnant?
2. The use o f anabolic steroids and/or testosterone precursors (including
androstenedione) can cause changes in the androgen levels in the body, which would
confound the results o f this study. Are you currently using, or have you ever used
anabolic steroids and/or testosterone precursors?
3. The use o f certain medications, over-the-counter medicines, or dietary supplements
could interfere with the results of this study. Are you currently taking any? I f yes,
please list.

4. The use o f healthy subjects is necessary for this study; certain disorders could
interfere with the results. Have you ever been diagnosed or hospitalized with a
chronic disease? I f yes, please explain.

S. Certain allergies could potentially compromise your participation in this study. Do
you have any allergies? If yes, please list the substances you are allergic to and the
type o f reaction to the substance.
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Human Subjects Protocol
THE ACUTE EFFECTS OF TRANSDERMAL TESTOSTERONE
PRECURSOR ADMINISTRATION ON SERUM STEROID
HORMONE LEVELS IN FEMALES
Name; Mark Rasmussen & Dr. John Young
Department; Kinesiology
Title o f Study; The Acute Effects o f Transdermal Testosterone Precursor Administration
on Serum Steroid Hormone Levels in Females
1 SUBJECTS;
Ten healthy UNLV female students w ill be recruited for participation in this study. An
informed consent form and questionnaire (see attached forms) w ill be used to alert the
test investigator o f any conditions that may affect participation in the study. The
questionnaire w ill be administered to the participants to survey medical history and any
past or present ergogenic aid use.
2. PURPOSE. METHODS. AND PROCEDURES;
Purpose
The purpose o f this study is to examine whether administration of the over-the-counter
dietary supplement and testosterone precursor, AndrosteDERM®, w ill affect the steroid
hormones androstenedione and testosterone (free and total). Research has shown that the
compounds androstenedione and androstenediol are precursors to the hormone
testosterone in the body. AndrosteDERM® contains the testosterone precursors
androstenedione and androstenediol. Dietary supplement companies recently marketed
these and similar compounds as ergogenic aids that are supposed to increase serum
testosterone levels in the body, thus producing the benefits of higher testosterone in the
body, including increased muscle strength and muscle hypertrophy. To date, research on
testosterone precursor supplementation has been performed on oral versions in males, and
has had mixed results. A new and supposedly superior version o f testosterone precursors,
transdermal (as in the supplement AndrosteDERM®), has been developed and is on the
market. To date, no research has been performed on AndrosteDERM®. Evaluation o f
the effects o f a new form o f supplement delivery (transdermal) may provide clear
answers as to whether or not testosterone precursor supplements raise serum testosterone
levels and thus, may enhance physical performance.
Procedures
Each participant w ill report to the Sports Injury Research Center for one six-hour testing
session. Prior to testing, each participant w ill be asked to complete an informed consent
form and an information questionnaire (see attached forms). Participants w ill be
informed o f the specific protocol o f the study, but w ill remain naïve as to the theoretical
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question. Following the introduction, specific instructions w ill be given prior to the start
of testing.
Using aseptic technique, a registered nurse w ill draw a baseline blood sample
(approximately 6-ml) from an antecubital vein (front o f the elbow). Next, 1 ml of
AndrosteDERM® w ill be applied to the inner surface o f the left upper arm. Every 45
minutes for the next six hours, another 6-ml sample o f blood w ill be drawn via
venipuncture. The total number o f venipunctures w ill be 9; the total amount o f blood
drawn w ill be approximately 54 mis.
3. RISKS:
For the proposed experiment the risk to the participant is minimal. A registered nurse
w ill draw all blood samples (using aseptic technique), and be present throughout the
entire testing period. The participant w ill also be allowed to stop testing at any time, for
any reason. There is always the risk o f bruising when blood samples are drawn. This
risk is minimized by using correct technique for blood drawing. There is a risk o f
infection when blood samples are drawn. The risk is minimized with the use o f
disinfectants, aseptic technique, sterile equipment, and latex gloves. Sterile, one time
use, disposable needles w ill be used. Universal blood and body fluid precautions w ill be
carried out at all times. Used needles w ill be disposed immediately after use in a sharps
container. The risk o f skin redness or irritation following the application o f the topical
cream is also possible. The possible effects are mitigated with the one-time application
o f a low dosage o f AndrosteDERM®.
Because this is a one-time single dose o f AndrosteDERM®, the potential risks associated
with testosterone precursor use are minimal. AndrosteDERM® is a testosterone
precursor that contains androstenedione and androstenediol, natural products found in all
humans. It is labeled as a dietary supplement and is available over-the-counter at health
food stores. It does not require a doctor’s prescription.
There are no known risks associated with the acute administration o f a testosterone
precursor. Most studies conducted on testosterone precursors have been performed on
males, with no side effects being reported with their acute (one-time) use. With chronic
use (eight weeks), a lowering o f HDL cholesterol was reported, although, the serum
concentration did not reach a level that is considered a risk factor for cardiovascular
disease (King et al., 1999). No negative side effects were reported in males who received
either 100 or 300 mg o f androstenedione daily for seven days (short-term); the authors
indicated that long-term use could be hazardous, particularly in women and children
(Leder et al., 2000).
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Some potential side effects associated with the chronic use o f testosterone precursors in
males include elevated estrogen levels, which may cause gynecomastia or other
feminizing effects, and may increase the risk for cardiovascular disease, and prostate and
pancreatic cancer (King et al ., 1999). In women, the chronic use of testosterone
precursors could elevate serum testosterone levels, possibly causing hirsutism or
virilization (Leder et al., 2000).
In the only known study on testosterone precursor administration in females, the female
participants ingested lOOmg of androstenedione (Mahesh and Greenblatt, 1962). Peak
testosterone levels were noticed 60 minutes after administration and had begun declining
90 minutes following administration (Mahesh and Greenblatt, 1962). No side effects
were reported with the one-time administration o f the androstenedione, or the transient
rise in testosterone (Mahesh and Greenblatt, 1962). In the only known study ever to
investigate the transdermal administration of a testosterone precursor, when the
androstenedione was administered to the male participants, no rise in serum
androstenedione, testosterone, or estradiol was reported (Stoppe and Krause, 1986).
The potential for side effects associated with the use of testosterone precursors in females
is mitigated by the one-time (not chronic) administration of a low dose (66.4 mg) of the
testosterone precursor. The effects of an acute (one-time) dose of AndrosteDERM® on
the menstrual cycle are unknown.
4. BENEFITS:
There are no known benefits or improvements for the participant as a result o f this
investigation. However, this study has the potential to contribute to the body o f scientific
knowledge on the subject of testosterone precursor supplementation.
5. RISKS-BENEFITS RATIO: The risks are minimized in this study by using a
registered nurse, and aseptic technique for all blood drawings. The participants are also
allowed to stop testing at any time, for any reason. The one-time administration of a low
dose of the testosterone precursor mitigates the possible side effects associated with it.
The benefits in regard to adding to the body o f scientific knowledge on the subject of
testosterone precursor supplementation and human performance are substantial; thus, the
risk-benefit ratio for this study is weighted highly in favor o f the benefits.
6. COSTS TO SUBJECTS:
There will be no costs to participants except for their time.
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7. INFORMED CONSENT:
Prior to agreeing to participate in this research project, each participant will be given an
informed consent form (see attached informed consent). After reading the form and
asking any questions, the individual can decide whether or not to participate. Those
individuals who choose to participate will be assigned a number based on their informed
consent; this number w ill be used for further identification of the participant, thus
insuring participant anonymity. The informed consents will be collected and stored in a
locked cabinet in the Sports Injury Research Center at UNLV. Those individuals who
choose not to participate will I* excused from the study.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

APPENDIX II
ANDROSTEDERM® PURITY ANALYSIS

91

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

92

9030 SouiN Rro Row, #100
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PRODUCT ANALYSIS
TO:
COMPANY
FAX NO:
DATE:

Mark Rasmusstn
University of Nevada, Las Vegas
(702) 895-2780
February 16, 2001

areducl Name;

P.O. Number:

latNumecr:

2KS1

AndrosteDERM

2LPOCSB362
Result

Unit

Androst-4 ene-3,17-dlone

21.8 A 0.26

mg/ml

Androst-4-ene-38,178-diol

44.6 1 0.37

mg/ml

Analyte

ptiformtd by HPLC, idimiOcMlon / quantification by axtamal ttandarOs method. Standards obtained
from SttraleMf Inc. Orlefly, the chromatographic condltlono SphcroMrb 00S2 CO (5 mum) column (12.5 cm
■ 4.0 mm) with a mobile phase (1.2 ml/min) of acetonlMle/1% tnethyiamin# (2:3). Methodology employed
as published by Class, RL Johnson, El, "Comparison of high-performance Uquld-ehromatographle and go*
chromatographic analyses of synthetic steroids* as published in ). Liq. Chromatogr., 1993, Vol. 10, No.lO,
PP 3543 3555

asmv

This Product Analysis Is subject to our Standard Terms.

ÉLJÂS

Oinesh Patel, Ph.D.
Director of Chemistry
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Androstwwdiofle Raw Data

t1

Sub)ect

Mean
StdOev
StdE

12

13

14

16

15

t7

t8

t9

1
2
3
4
S
6
7

Counts'
13158
10835
2054
10178
4909
9887
8044

13192
3523
7970
10222
8331
4232
11429

12710
11519
7772
8247
8785
10574
11662

12520
11874
7944
9622
8990
10809
11944

12831
11954
7366
7526
9247
11168
11326

13313
11888
9803
9723
8893
10247
9065

14143
11746
7983
8079
8766
10433
9731

14126
11503
7530
5308
7785
9622
1171

13799
12264
7290
10228
8462
10099
10945

1
2
3
4
5
6
7

% Bound"
55.28107
45.52138
8.829527
42.78111
20.82432
41.53853
33.79548

55.42391
14.80128
33.48458
42.94597
35.00126
17.78002
48.01697

53.39887
48.39509
32.65272
34.84835
38.90866
44.42484
48.99588

52.60062
49.0463
33.37535
40.42517
37.76994
44.57188
50.18066

53.90723
50.22267
30.94698
31.81919
38.84968
46.92043
47.58424

55.93227
49.94538
41.18561
40.84951
37.36241
43.051
38.08503

59.41938
49.34879
33.5392
33.94253
36.82884
43.83245
40.88312

59.34795
48.32787
31.636
22.30065
32.62331
40.42517
4.919755

57.97412
51.52508
30.62768
42.97118
35.55163
42.42921
45.98353

1
2
3
4
5
6
7

Log"
0.225419
0.523043
1.848069
0.607218
1.282285
0.644501
0.880627

0.221063
1.45986
0.890108
0.601581
0.843856
1.369022
0.446939

0.282817
0.435408
0.915476
0.854619
0.78569
0.556482
0.417087

0.30716
0.41555
0.893439
0.878453
0.759425
0.551998
0.380957

0.267314
0.379676
0.967493
0.946993
0.726498
0.480379
0.480136

0.20558
0.388132
0.655263
0.865513
0.771853
0.598378
0.749816

0.09922
0.406325
0.888442
0.878143
0.788124
0.574547
0.664488

0.101398
0.437458
0.946481
1.231165
0.916373
0.678453
1.781199

0.143293
0.339958
0.97723
0.600812
0.827073
0.817339
0.508949

1
2
3
4
5
6
7

ng/ml*
1.880423
3.334592
44.47017
4.047789
19.15512
4.410633
7.596735

1.883653
28.83101
7.7644
3.995587
6.980016
23.38958
2.798589

1.917859
2.725262
8.231439
7.155147
8.105057
3.601489
2.612885

2.028428
2.603452
7.824184
4.78928
5.748788
3.564494
2.404125

1.850607
2.397043
9.278819
8.851022
5.327188
3.022585
2.884931

1.605314
2.444172
4.521297
4.629272
5.91361
3.966227
5.621031

1.256666
2.548736
7.73468
7.5187
8.139373
3.754457
4.618359

1.262985
2.738158
8.840584
17.02804
8.248455
4.76928
57.70311

1.390892
2.187552
9.489206
3.98852
8.715411
4.143233
3.228118

12.09935 10.77489 4.621277 4.134393 4.801742 4.100132 4.795853 14.37009 4.44899
15.42318 10.81059 2.504433 2.110092 3.110421 1.583427 2.46803 19.79957 2.792924
5.829414 4.086018 0.946587 0.79754 1.175629 0.598479 0.932828 7.483536 1.055628

"Counts. actual numlMr lacalvsd during radioimmunoassay (not count)
*% Bound - net countftnaxlmum Itinding count X 100
"Log • And tag of % Bound
*ng/mi - Actual androstenedione concentration in ng/ml

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

95
Free Testostaront Raw Data

t1

Mean
StdOev
StdE

t4

I13

12

15

17

t6

t9

t8

1
2
3
4
5
6
7

Counts'
19332
20735
2502
15455
10708
15218
13684

22409
15625
10082
12150
11557
6446
18486

22139
20830
9059
10015
12498
16780
19999

22658
20682
10267
11605
16161
17867
19382

21249
21108
8192
6782
15126
17140
17658

21862
19805
13932
15324
14667
15614
14420

21201
19756
6840
10959
11542
17099
14360

19695
17700
8592
12859
12462
15393
5513

20057
19668
6064
14746
15058
15368
14006

1
2
3
4
5
6
7

% Bound'
74.877992
80.312185
9.6909133
59.881337
41.47494
58.943373
53.001782

86.79603
60.51979
39.05028
47.06019
44.76334
24.96708
71.60121

85.75025
80.68015
35.08792
38.79077
48.40809
64.99342
77.46146

67.76048
80.1069
39.76883
44.94926
62.59586
69.20366
75.07166

82.30304
81.75691
31.7298
26.26849
58.58703
68.38779
68.39414

64.67736
76.71005
53.96235
59.35394
56.8092
60.47719
55.85251

62.11713
76.52026
34.23968
42.44713
44.70524
68.22899
55.62011

76.28399
88.55682
33.27911
49.60634
4626865
59.62119
21.35332

77.66611
76.95406
31.23402
57.11519
56.32365
59.60183
54.25672

1
2
3
4
5
6
7

Log'
0.332061 4.029059
0.1674034 0.767118
2.3072474 1.417651
0.7870697 1.174948
1.3441827 1.244543
0.6148843 1.844375
0.9949162 0.431348

0.002628
0.156254
1.537711
1.425514
1.1341()6
0.631566
0.253781

4)058282
0.173624
1.395939
1.23891
0.704213
0.503995
0.326193

0.10708
0.123828
1.639463
1.604942
0.625682
0589318
0.528523

0.035138 0.112713 0.289459 0.246974
0Z76549
0.2823 0.523594 0.269155
0.965811 1.563413 1.592519 1.654485
0.602444 1.314725 1.091739 0.870279
0.87955 1.246304 1.138331 0.833662
0.788409 0.594128 0.794346 0.794933
0.908538 0.91558 1.953873 0.956691

1
2
3
4
5
6
7

pgMil'
2.148132
1.4702914
202.88382
6.1244875
22.089335
6.529566
9.6836229

1.006071
1.433026
34.49142
26.63875
13.81778
4.281208
1.793829

0.874416
1.491501
24.88507
17.33444
5.060726
3.1915
2.119302

1.279616
1.329314
43.59765
63.81784
6.693938
3.684332
3.37694

1.08427
1.89038
9.242951
6.345181
7.577924
5.666909
8.100996

0.935279
5.849495
26.18078
14.96057
17.58075
69.88363
2.699905

1.296323
1.915578
36.59427
20.64073
17.63208
3.927808
8.233417

1.947417
3.338829
39.13079
12.35205
13.75091
6.227965
89.92352

1.765933
1.85847
45.13207
7.417882
6.81608
6.236385
9.055057

35.875608 19.72149 11.89458 7.850994 17.71138 5.729802 12.69143 23.81021 11.18341
25.3388 3.111804 12.91642 31.73947 15.22275
73.965056 23.87512 13.65831 9.412404
5.75366
27.956163 9.023947 5.161601 3.557554 9.577164 1.176151 4.862703 11.99639

‘ Counts • actual numlMr received during radkÉnmunoaasay (net count)
*% Bound • net count/maximum tiinding count X 100
‘ Log • Anti log of % Bound
‘pg/mi • Actual tree testosterone concentration in pg/ml
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Total Tntotlwona Raw Data

SutHect

Mean
StdOev
Std E

t1

13

12

t4

t5

17

t6

18

t9

1
2
3
4
5
6
7

Counts*
12269
11794
1390
10796
9823
10151
9040

14077
9743
10692
10565
4975
6458
11624

12695
11728
9265
8491
10099
10774
11706

13067
11329
9374
9641
11090
10501
11278

12620
11535
7181
7322
10620
9917
10466

13143
11246
9490
10637
10547
9161
9436

13407
10675
7632
9013
9211
9272
9180

11608
10397
7180
10515
9280
6539
4337

12669
10334
7038
9493
10041
8203
10598

1
2
3
4
5
8
7

% Bound*
81.042341
77.904749
9.181584
71.312504
64.885395
67.051985
59.713323

92.98501
84.35696
70.62554
69.78664
32.86214
42.65804
78.78182

83.85627
77.46879
61.19955
56.08693
66.7085
71.18718
77.32347

88.31349
74.83321
61.91955
63.6832
73.25451
69.36389
74.49633

83.36066
76.19394
47.43378
48.36515
70.14994
65.50631
69.1327

66.81551
74.28496
62.68578
70.26224
69.66775
60.64469
62.32908

68.55935
71.83434
50.41284
59.53498
60.84286
61.24579
60.63809

76.67613
68.67693
47.42717
69.45637
61.29863
56.40399
28.64786

63.68452
68.26078
46.4892
62.70559
66.32538
54.18456
70.00462

1
2
3
4
5
6
7

Log*
1.3821095 1.027275 1.298504
1.475332 1.877857 1.488285
3.5172005 1.691608 1.971669
1.8711975 1.718533 2.123572
1.8621566 2.813615 1.807989
1.797784 2.522565 1.875515
2.0158266 1.508696 1.492603

1.225496 1.313223
1.566592 1.526163
1.950276 2.38067
1.897876 2.352998
1.613498 1.705739
1.729094 1.843708
1.576601 1.735963

1.21058 1.158768 1.511836 1.303606
1.582881 1.655693 1.749504 1.761869
1.927511 2.292158 2.380867 2.408735
1.702403 2.021126 1.726346 1.926922
1.720066 1.982267 1.968725 1.819372
1.968154 1.970295 2.114152 2.160095
1.936108 1.988351 2.938828 1.710057

1
2
3
4
5
6
7

ng/dr
24.105131
29.87666
3290.0346
46.902668
72.804228
62.774602
103.71143

16.80721
36.86311
89.18184
79.04521
41.06745
53.59122
37.72256

16.23977
38.27202
64.62731
50.39675
52.4687
97.30928
66.71784

10.64817
75.48441
49.1596
52.06347
651.0517
333.0925
32.26234

1988399
30.78117
9368468
132.9145
64.2672
47.37129
31.08871

20.56946
33.58635
240.2538
225.4228
50.78541
69.77637
54.44559

14.41345
45.25777
195.9557
104.9846
95.99896
93.38879
97.35326

32.49846
56.17001
240.3624
53.25324
93.05178
130.0624
8686165

20.11899
57.79214
256.2921
64.51265
65.97393
151.3891
51.29283

171.966 59.99879 50.61123 99.26283 60.86453 92.47893 210.5733 98.19596
516.60133
1222.3861 237.9748 40.67712 25.47544 92.67231 29.56011 56.60517 298.4691
60.5996
462.01852 89.94603 15.37451 9.628811 35.02684 11.17267 21.39474 112.8107 30.46378

'Counta • actual numlwr racalvad diaing radjoinununcastay (net count)
*% Bound • net count/maittmNn tiinding count X 100
*Log • And log of % Bound
"ng/dl • Actual total taatoetemne concentration in ng/dl
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